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Abstract
Objective: This pilot study aimed to advance our current understanding of the role of
biological processes in the development of specific neuropsychiatric complications in
HIV/AIDS. In particular, this project explored whether elevated systemic indicators of
immune system (i.e., IL-6, TNF-alpha, and neopterin) and hypothalamic-pituitary adrenal
axis (HPA) activation (i.e., cortisol) were associated with commonly reported clinical
symptoms of cognitive impairment, fatigue, and depression.
Method: Thirty-one HAART-nalve adults (i.e., no past or current use of antiretroviral
medications) adults with HIV infection completed subjective symptom questionnaires
and neuropsychological tests. Blood samples were obtained and processed at three
separate laboratories. One-tailed Spearman correlations were used to examine the
relations between serum concentrations of immune and HP A factors, cognitive
impairments

(learning

efficiency,

attention/working

memory,

and psychomotor

processing speed), and subjective symptoms (fatigue, depression, cognitive complaints,
and general illnesses).
Results: Neuropsychological impairment was not associated with the levels of biological
markers. Depressive symptoms were, however, modestly associated with elevated IL-6
mRNA expression (rs = 0.40, p < .05) even after removing the influences of fatigue, total
cognitive complaints, and illness symptoms (pr = 0.39, p < .05). Elevated serum
neopterin was strongly associated with depressive symptoms in individuals taking
antidepressants (rs = 0.83,/? < .001), though the association was nullified in the group not
taking any antidepressants (r„ = -0.25, p > .05). More specifically, mean neopterin levels
were higher in the depressed as compared with non-depressed group but only for those
individuals taking antidepressants [F(l, 11) = 45.66,/? < .001].
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Conclusion: Increased subjective symptoms, especially depression, may be associated
with elevated immune activation (i.e., higher levels of IL-6 mRNA and neopterin) in
some

individuals

with

HIV

infection.

While

antidepressants

may -exert

immunosuppressive effects in treatment-responsive individuals, treatment-resistant
individuals may continue to have both elevated depressive symptoms and neopterin
levels despite presumably therapeutic doses of antidepressants. Although replication in a
larger sample is needed, these preliminary findings suggest that systemic biological
markers (especially neopterin) may be useful in differentiating individuals at greater risk
o f developing

chronic,

debilitating

depression.

Implementation

of alternative

interventions may be necessary to alleviate depressive symptoms in this selective group
and ultimately improve their quality of life.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Acknowledgements
I would like to express my sincere appreciation to the numerous individuals who
guided me through the progression of this dissertation with their knowledge, support, and
encouragement. First, I would like to acknowledge the contributions of my committee
members. Dr. B. Rourke has been an invaluable mentor during my training at the
University of Windsor. His teaching has played an integral role in my clinical and
research pursuits in neuropsychology to date. This project would not have been possible
without the dedication of Dr. S. Rourke and his staff at St. Michael’s Hospital
Neurobehavioural Research Unit. I am incredibly grateful for the time and expertise that
Dr. S. Rourke has devoted to both this project and my professional development. I would
like to thank Dr. L. Buchanan and Dr. M. Drake for their meaningful and practical
suggestions, as their combined comments have greatly improved the quality of this
research project. Next, I would like to acknowledge the time-intensive contributions of
the University o f Toronto lab (M. Hycza, Dr. M. Ostrowski, and Dr. S. Der), J. Alick
Little Lipid lab (Dr. P. Connelly and M. Lee), and St. Michael’s Hospital Core lab (C.
Edgar) in processing the biological assays. I would like to thank the St. Michael’s
Hospital Positive Care Clinic (Dr. K. Gough, S. Martinez, and M. Lampitoc) for their
assistance with drawing the blood samples and recruiting participants, as well as
physicians at other HIV clinics in Toronto for their assistance with recruitment.
Moreover, I would like to recognize the organizations that financially supported this
project: Ontario HIV Treatment Network (OHTN) studentship to myself and OHTN and
Canadian Foundation for AIDS Research operating grants to Dr. S. Rourke. Lastly, I
would like to thank my family, friends, and colleagues for their continual encouragement
and support of my enduring academic endeavours.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table of Contents
ABSTRACT
ACKNOWLEDGEMENTS

........
.........

iii
v

LIST OF T A B L E S ................

...vlii
....................Ix

LIST OF FIGURES..................
CHAPTER
I.

INTRODUCTION................................................................... ............................ 1
Prevalence and functional impact of cognitive symptoms in HTV/AIDS ......
3
Prevalence and functional impact of chronic fatigue and depression in HTV/AIDS....5
Contribution of multiple factors to the manifestation of these symptoms. ............6
Cognitive symptoms......................................
.6
Somatic and depressive symptoms................................................................7
Biological factors may mediate symptom manifestation: “Illness behaviour”..
10
Infection-initiated responses.............. ...................................................... 11
Stress-initiated responses.................................
13
Investigations of biological correlates of fatigue, cognitive symptoms, and depression
in healthy controls, medical illnesses, and mood disorders......................................15
Healthy adults with immune or HPA activation elicited under experimental
conditions...............................
16
Medical conditions..................................................................................... 18
Mood disorders............................
..22
Potential neural correlates of “illness behaviour”.

......................

33

The neuropathology of HIV: At system, cellular, and molecular levels...................35
Brain regions...............
35
Biological mechanisms
..................
36
CD4T cells and Viral Load
...........................
...39
Neopterin .......
40
IL-6 and TNF-alpha. ..........
41
Cortisol
........
43
Summary. .......................
Study Objective and Predictions
II.

44
...............

METHODOLOGY..................
Participants
...................
Procedure............

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

45
48
48
..52

Measures
................
52
Demographic background
........
..52
Disease status
............................................
.53
Subjective symptoms. .........
Attention and working memory
...........
.55
Psychomotor efficiency and processing speed.
................................55
Learning efficiency and memory.
...... .................. ..........................56
Composite deficit ratings.
..............................
Biological assays.
.......
...58
iriRNA expression.........................
58
Serum protein concentration levels...............
59
III.

RESULTS.
...........
Performance on neuropsychological deficit indices.......................
Associations between symptom measures

60
60

...............................................61

Associations between the various biological indicators

.......

61

Associations between symptom measures and neuropsychological performance

66

Associations between biological indicators and neuropsychological performance...67
Associations between biological indicators and symptom measures.................

69

Associations between severity of depression and IL-6 mRNA and neopterin levels. .70
Potential confounding influences on the biological measures..................................75
Interactions with antidepressant medications............
75
Sex
....................
..83
Disease stage..................................................................
83
IV.

DISCUSSION
.............................
Evaluation of Predictions and Study Limitations.............................
Hypothesis 1........
Symptom measures....................................................
Cognitive impairment........................................
Hypothesis 2 ..................
Hypothesis 3
.........................................................................
Hypotheses 4 & 5
................................
Clinical Implications and Directions for Future Research.

..............

86
87
87
88
90
92
94
96
98

APPENDIX A: Preliminary Analyses of the HAART-stable participants............ 103
REFERENCES..................................

116

VITA AUCTORIS......................

163

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

..5

...57

List of Tables
Tables

Page

1. Selected studies comparing the link between fatigue and biological markers

..... 24

2. Selected studies comparing the link between cognitive function and biological markers.

26

3. Selected studies comparing the link between depression and biological markers............... ..29
4. Selected studies investigating the effects of antidepressants on biological indicators............32
5. Demographics for HAART-nai've sample (N=3l) ................................................................ 50
6. Means and standard deviations of the biological indicators, symptom measures, and
neuropsychological deficit scores for the HAART-naive sample (N = 31).....................

.51

7. Frequencies of individuals within impairment ranges across total and domain-specific
neuropsychological deficit indices within the HAART-naive sample (JV= 31)...............

..62

8. Spearman correlations (rs) showing the association between the total and domain-specific
neuropsychological deficit ratings within the HAART-naiVe sample (N= 31)........................... 63
9. Spearman correlations (rs) showing the association between various symptom measures
within the HAART-nai've sample (iV=31)..............................................................

64

10. Spearman correlations (rs) showing the association of the biological indicators within the
HAART-nai've sample (N - 31).....................................................................................
65
11. Spearman correlations (rs) showing the association between various symptom measures and
neuropsychological deficit scores within the HAART-nai've sample (iV=31)........................ ...67
12. Spearman correlations (rs) showing the association of the biological indicators and measures
of depression, fatigue, illness symptoms, cognitive symptoms, and cognitive deficit indices within
the HAART-na'fve sample ( N - 31)..............
...68
13. Demographic data, biological indicators, and symptom measures for HAART-nai've
individuals on (n —13) and not on antidepressants (n - 18)............
14. Demographics for the HAART-stable sample (n = 13).................
15. Mean and standard deviations of the biological indicators, symptom measures, and
neuropsychological deficit scores in the HAART-stable sample(N =13).........................

78
..105
106

16. Frequencies of individuals within impairment ranges across total and domain-specific
neuropsychological deficit indices for the HAART-stable sample (n = 13).............................. 107
17. Spearman correlations {rs) showing the association of the biological indicators and measures
of depression, fatigue, cognitive symptoms, and neuropsychological deficit ratings within the
HAART-stable sample (N= 13)........
109

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

List of Figures
Figure

Page

1. Relations between depression, somatic symptoms, neuropsychological performance,
and cognitive symptoms in HIV/AIDS............................

......9

2. Complex interconnections between the central nervous system, hypothalamic-pituitary axis,
and immune system forming a reciprocal inhibitory feedback mechanism that mediates various
physiological and behavioural responses. ...... ............................................. ...................... . 12
3. Scatterplot showing IL-6 mRNA expression for individual participants divided according to
the severity of their depressive symptoms..............
71
4. Scatterplot showing serum neopterin concentrations for individual participants divided
according to the severity of their depressive symptoms.............................
5. Mean IL-6 mRNA expression as a function of depression severity.

72

..... ............. . ..73

6. Mean serum neopterin concentrations as a function of depression severity.

................. ....74

7. Scatterplot showing the relations between depressive symptoms and serum neopterin levels
separated by antidepressant groups.......................................................................................... ..79
8. Scatterplots showing the relations between depressive symptoms and IL-6 mRNA expression
separated by antidepressant groups
............................................................
80
9. Scatterplots showing the relations between depressive symptoms and serum neopterin levels
separated by antidepressant groups. ...................................
81
10. Mean serum neopterin concentrations for depressed and non-depressed individuals separated
by antidepressant groups...............................................
82
11. Scatterplot showing serum neopterin levels across disease stage

......

12. Scatterplot showing the relations between TNF-alpha mRNA expression and total
neuropsychological deficit ratings in the HAART-stable sample......................
13. Scatterplot showing the relations between IL-6 mRNA expression and total
neuropsychological deficit ratings in the HAART-stable sample...............................

....85
...110
I ll

14. Scatterplot showing the relations between serum TNF-alpha concentrations and total
neuropsychological deficit ratings in the HAART-stable sample ......... ............. ................112
15. Scatterplot showing the relations between serum IL-6 concentrations and total
neuropsychological deficit ratings in the HAART-stable sample........................
16. Scatterplot showing the relations between serum neopterin concentrations and total
neuropsychological deficit ratings in the HAART-stable sample.................

113
..114

17. Scatterplot showing the relations between serum cortisol concentrations and total
neuropsychological deficit ratings in the HAART-stable sample.............................................. 115

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1

CHAPTER 1
Introduction
Since the human immunodeficiency virus (HIV) was identified as the causative
agent for Acquired Immunodeficiency Syndrome (AIDS) in 1984, extensive research has
been aimed at decelerating the worldwide spread of this devastating and life-threatening
disease (Gallo et al., 1984). Initial investigations primarily centred around delineating the
pathogenesis o f HIV in attempt to develop drug therapies that interfere with the viral
invasion and replication process. Combination highly active antiretroviral therapy
(HAART) agents have proven effective at slowing disease progression (Carpenter et al.,
2000; Chaisson, 1998; Sendi, Bucher, Craig, Pfluger, & Battegay, 1999), though
considerable variability in the rate of progression and clinical course of HIV infection
still exists (Bouwman et al., 1998; Weber, 2001). New issues in clinical management
have concurrently emerged with medical advancements and prolonged life expectancy.
Individuals with HIV infection frequently report that the presence of cognitive
impairments, somatic symptoms (especially chronic fatigue), and/or psychiatric
difficulties adversely impacts their activities of daily living and quality of life. The causes
and pathological processes underlying these symptoms in HIV/AIDS remains unclear.
More multidisciplinary research is needed to identify specific factors (both biological and
psychosocial) that explain some of the variability in clinical manifestations and predict
at-risk individuals suitable for early interventions aimed at managing clinical symptoms
and improving quality of life.
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2
Recent work in the area of psychoneuroimmunology highlights the need to
consider the role biological processes play in mediating somatic, cognitive, and
psychological symptoms in various illnesses. Although the significance of cytokine and
hypothalamic-pituitary-adrenal (HPA) dysregulation in the neuropathogenesis of HIV has
been described at a cellular mechanistic level (e.g., Brooke & Sapolsky, 2000;
Gendelman, Lipton, Tardieu, Bukrinksy, & Nottet et al., 1994; Goodkin, Baldewicz,
Wilkie, Tyll, & Shapshak, 2001; Kumar, Kumar, Waldrop, Antoni, & Eisdorfer, 2003),
generalization o f these findings to the broader clinical level is not readily apparent. To
date, studies have generally focused on determining systemic (e.g., CD4 cell count, viral
load, and cytokine) or central nervous system (CNS) (e.g., levels of HIV gpl20 viral
proteins or neurotoxin production) biological markers of global levels of neurological
functioning and disease progression in HIV/AIDS (e.g., Brookes & Sapolsky, 2000;
Childs et al., 1999; Dal Pan et al., 1998; Griffin, McArthur, & Comblath, 1991; Ryan et
al., 2001). Various psychosocial risk factors have also been related to overall disease
progression in HIV and the development of HIV-related medical symptoms, though more
research is needed to delineate the immunological and neuroendocrine mechanisms
suspected of influencing this relationship (e.g., Balbin, Ironson, & Solomon, 1999; Cole,
Kemeny, Fahey, Zack, & Naliboff, 2003; Kemeny, 2003). A paucity of literature still
exists on the pathophysiology underlying the manifestation of specific neuropsychiatric
complications in HIV/AIDS.
This exploratory study was designed to expand upon these previous studies by
investigating the potential link between systemic biological markers (i.e., cortisol, IL-6,
TNF-alpha, and neopterin) and the presence of specific clinical symptoms in adults with
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HIV/AIDS: cognitive impairments (i.e., attention and working memory, learning
efficiency, and psychomotor/processing speed), fatigue, and depression. In the following
sections, current literature providing the rationale for this pilot project will be outlined in
more detail. First, the prevalence, functional implications, and potential relations between
cognitive, somatic, and depressive symptoms will be reviewed. Next, a brief overview of
the physiological and behavioural changes associated with activation of immuneendocrine-neurotransmitter

pathways

will

be

provided.

The

brain-behavioural

consequences of dysregulation of this biological pathway documented in previous studies
of healthy controls, other medical illnesses, and mood disorders will be described. Then,
possible biological mechanisms contributing to brain-behaviour dysfunction in HIV
infection will be reviewed at systems, cellular, and molecular levels. Finally, the goals
and hypotheses of the present study will be outlined.

Prevalence andfunctional impact o f cognitive symptoms in HIV/AIDS
Self-reports of cognitive symptoms, occurring in about 40 to 50% of adults with
HIV infection, commonly include slowed thinking, reduced attention span, increased
distractibility, forgetfulness, difficulty at simultaneously completing more than one task,
and blocking on words (Gibbs, Andrewes, Szmukler, Mulhall, & Bowden, 1990; Mehta
et al., 1996). A similar proportion of individuals demonstrate cognitive impairments on
neuropsychological tests, with the prevalence estimated to increase with advancing
disease stage from about 30% of asymptomatic individuals to 56% of individuals
diagnosed with AIDS (Bomstein et al., 1993; Heaton et al., 1995; White et al., 1995).
Cognitive impairments can range from milder difficulties primarily seen in areas of
attention

and

working

memory,

verbal

fluency,

learning

efficiency,
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and

psychomotor/processing speed (MCMD: HIV-associated minor cognitive/motor disorder)
to profound dementia (HAD: HIV-associated dementia complex) (Janssen et al., 1991).
Despite advances in HAART medication, HAD continues to develop in about 15% of
individuals with AIDS (McArthur, Sacktor, & Seines, 1999). HAD resembles a
subcortical pattern o f dysfunction characterized by slowed cognitive processing, impaired
recall of information, problems with attention/concentration, motor disturbances (e.g.,
slowing, unsteady gait, tremor, and leg weakness) and behavioural changes (e.g., apathy,
irritability, loss of libido, and social withdrawal).
These cognitive difficulties can adversely affect everyday functioning to varying
degrees. Studies have documented associations between cognitive impairments in
individuals with HIV infection and poorer quality of life (Kaplan et al., 1995; Tozzi et al.,
2004), higher rates of unemployment and decreased work efficiency for those still
employed (Albert et al., 1995; Benedict, Mezhir, Walsh, & Hewitt, 2000; Heaton et al.,
1996; Heaton et al., 1994; Rabkin, McElhiney, Ferrando, VanGorp & Lin, 2004),
problems with medication adherence (Albert et al., 1998), and higher risk for mortality
(Ellis et al., 1997; Mayeux et al., 1993; Sacktor et al., 1996; Wilkie et al., 1998).
Recently, Heaton et al. (2004) reported an association between neuropsychological
impairment and poorer performance on functional measures similar to everyday tasks
(e.g., shopping, cooking, finances, medication management, and vocational abilities).
In summary, cognitive impairments remain prevalent despite advancements in
antiretroviral drug therapies and these symptoms can negatively impact quality of life for
individuals with HIV/AIDS.
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Prevalence and functional impact o f chronic fatigue and depression in HIV/AIDS
Fatigue and mood disturbance (especially depression and anxiety) are often
present in many individuals with chronic illnesses, and are identified as the most
challenging and debilitating symptoms to manage (e.g., Barroso et al., 2002; Denburg,
Carbotte, & Denburg, 1997; Swain, 2000). Chronic fatigue is the most frequently
reported symptom of patients with HIV and their health care providers, with estimates
ranging from about 20% of asymptomatic individuals with HIV infection to about 40% of
adults diagnosed with AIDS (Ferrando et al., 1998; Justice, Rabeneck, Hays, Wu, &
Bozzette, 1999). Depression and anxiety are also prevalent in individuals with HIV, with
estimates ranging from about 5 to 25% (Ciesla & Roberts, 2001; Grant & Atkinson,
1990). Although depressive symptoms and fatigue are often highly correlated (e.g.,
Kalichman, Sikkema, & Somlai, 1995; O’Dell, Meighen, & Riggs, 1996; Perkins et al.,
1995), fatigue may remain in some individuals even after the alleviation of depressive
symptoms (Ferrando et al., 1998). Fatigue and depression in adults with HIV have been
associated with poorer quality o f life and greater functional limitations, including poorer
physical functioning, disability status, and difficulties maintaining employment (e.g.,
Cleary et al., 1993; Ferrando et al., 1998; Fleishman & Crystal, 1998; Justice et al., 1999;
Rabkin et al., 2004).
In summary, many individuals with HIV suffer from psychiatric conditions
(especially depressed mood) and chronic fatigue. These debilitating symptoms can affect
their daily functioning and consequently their overall satisfaction with life.
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Contribution o f multiple factors to the manifestation o f these symptoms
Given that these symptoms adversely affect quality of life, more attention needs
to be directed toward investigating specific factors that may account for the variability in
clinical manifestations across individuals with HIV/AIDS.
Cognitive symptoms. A series of ongoing studies conducted at S t Michael’s
Hospital within the Neurobehavioural Research Unit have aimed to clarify the source and
clinical significance of cognitive symptoms in individuals with HIV infection by
quantifying the independent contributions of various factors: (a) depressive symptoms;
(b) brain functioning (as measured by neuropsychological test performance); (c) medical
symptoms; and (d) fatigue. Multiple linear regressions and confirmatory factor analytic
approaches have been employed to examine the relations between these symptoms. The
following findings are summarized in Figure 1.
Depressive symptoms have consistently accounted for the majority o f the variance
across various domains of self-reported cognitive symptoms (e.g., memory, language,
sensory-motor, and executive problems) (Bassel, Rourke, Halman, & Smith, 2002;
Rourke et al., 1999a and 1999b). Other studies have similarly found that depressive
symptoms are moderately correlated with subjective cognitive difficulties in adults with
HIV/AIDS (e.g., Beason-Hazen, Nasrallah, & Bomstein, 1994; Hinkin et al., 1996;
Mapou et al., 1993; Moore et al., 1997; van Gorp et al., 1991; Wilkins et al., 1991).
A recent structural equation modeling study using a sample o f 160 adults with
HIV infection showed that depression and medical symptoms were highly correlated.
Both of these symptoms were also independently associated with overall cognitive
symptoms (Carter, Rourke, Murji, Shore, & Rourke, 2003). Millikin, Rourke, Halman,
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and Power (2003) also found that fatigue, even after statistically controlling for
depressive symptoms, was associated with subjective cognitive symptoms in a group of

68 men with HIV infection.
Some studies using multiple regressions analyses have also found that
performance on neuropsychological tests, in particular complex psychomotor efficiency
and working memory measures, independently accounted for a significant proportion of
the variance across cognitive symptom domains even after the large influence of
depression was removed (Bassel et al., 2002; Rourke et al., 1999a). Carter et al. (2003)
similarly showed that neuropsychological performance was independently associated
with cognitive symptoms, though not correlated with depression and medical symptoms.
While some studies have supported this finding (e.g., Beason-Hazen et al., 1994; Lopez,
Wess, Sanchez, Dew, & Becker, 1998; Mapou et al., 1993; Poutianinen & Elovaara,
1996), others have failed to obtain an association between self-reported cognitive
symptoms and neuropsychological functioning (e.g., Hinkin et al., 1996; Moore et al.,
1997; van Gorp et al., 1991). The discrepant findings in the literature may be attributable,
at least in part, to variable sample sizes, the breadth and type of cognitive symptoms
tapped by questionnaires, and the different domains of neuropsychological functions
measured.

Somatic and depressive symptoms. Disruption o f physiological processes
associated with the invasion and replication of the HIV virus likely contributes to the
manifestation o f some constitutional symptoms (Fell et al., 1993). Fluctuations in mood,
energy level, appetite, and sleep patterns may also arise from prolonged exposure to
stressful events or problems with adjusting and coping to life circumstances. Individuals
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with HIV often experience significant psychosocial stressors throughout the course of
their chronic illness, especially at transition points (e.g., discovery o f seropositive status,
initiation o f HAART medications, or diagnosis of AIDS). Longitudinal studies have
identified associations between certain psychosocial characteristics (e.g., stressful life
events, denial/avoidance coping style, chronic depression, bereavement, and social
isolation) and accelerated disease progression (e.g., Balbin, Ironson, & Solomon, 1999;
Cole, Kemeny, Fahey, Zack, & Naliboff, 2003; Kemeny, 2003). Interestingly, some of
these studies have also documented accompanying immunological and endocrine changes
that may mediate the relation between psychosocial factors and disease progression. For
example, Reed, Kemeny, Taylor, and Visscher (1999) noted that individuals with
negative expectancies about their prognosis who recently experienced the death of a close
friend to AIDS showed increased risk of developing HIV-related somatic symptoms over
the next 2.5 to 3.5 years and an accelerated rate of mortality. Declines in CD4 T cell
counts and elevations in serum markers of immune activation were observed to
accompany this deterioration.
Moreover, a series of studies from the Behavioural Medicine Program at the
University of Miami have demonstrated that interventions geared toward managing stress
and developing positive coping strategies in individuals with HIV led to improvements in
mood along with alterations in neuroendocrine functioning and immunological status
(e.g., Antoni, 2003; Antoni et al., 1991; Antoni et al., 2000). These studies suggest that a
better understanding of the interaction between psychological and physiological factors
may be pivotal to managing depression and fatigue in individuals with HIV infection.
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Biologicalfactors may mediate symptom manifestation: “Illness behaviour”
While depression, fatigue, medical symptoms, and neuropsychological measures
of brain functioning are associated with the presence of self-reported cognitive symptoms
in some individuals with HIV/AIDS (see Figure 1), a significant proportion of the
variability in clinical manifestation remains unexplained. A growing body of evidence
within the field o f psychoneuroimmunology suggests that systemic alterations in
biological processes may mediate some of the somatic, mood, and cognitive changes seen
in various immune-based illnesses. The regulation of biological activities is linked by
common molecules (cytokines and hormones) and the distribution of their receptors
throughout the body. These biological signals act on different tissues, including regions
of the brain, to initiate and terminate different physiological and behavioural responses.
Functions of the hippocampus, hypothalamus, basal ganglia, and prefrontal cortex
connections may be particularly sensitive to fluctuations in cortisol or proinflammatory
cytokines due to the high density of receptors located within these brain regions (e.g.,
Alderson & Novak, 2002; Bethea, Chung, Sapracio, Gillespie, & Benveniste, 1992;
Heffelfinger & Newcomer, 2001; Lin, Amaral, Brosnan, & Lee, 1998; Rothwell &
Luheshi, 1994). Recent investigations have demonstrated that cytokines can affect neural
functioning both locally by their direct presence in brain tissue and systemically through
stimulation o f cranial nerves and crossing the blood-brain barrier at designated areas (for
review see Kronfol & Remick, 2000; Maier, Goehler, Fleshner, & Watkins, 1998;
Watkins, Maier, & Goehler, 1995). More specifically, reciprocal inhibitory feedback
loops (see Figure 2) involving proinflammatory cytokines (e.g., IL-1, IL-6, and TNFalpha) and hypothalamic-pituitary-adrenal (HPA) products (e.g., cortisol) are important
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for the homeostatic modulation of biological processes induced in response to infection
and to physical or psychological stress.

Infection-initiated responses. When the body is invaded with a foreign molecule
or pathogen, scavenger immune cells (e.g., macrophages) recognize, engulf, and destroy
the invader. This process signals the release of proinflammatory cytokines that act to
en h a n c e

the immune response by recruiting and activating other immune mechanisms

(i.e., cell-mediated and humoral immunity involving T and B lymphocytes). Along with
enhancing immune activity, cytokines signal the brain to produce physiological changes
that slow down certain activities in order to redirect energy and resources toward other
processes necessary for combating infection and promoting recovery (Janeway &
Travers, 1997; Maier, Watkins, & Fleshner, 1994). The resultant changes are often
collectively referred to as “illness or sickness behaviour:” fever, malaise, fatigue,
depressed mood, decreased appetite, accelerated weight loss, increased need for sleep,
reduced sex drive, increased sensitivity to pain, and reduced cognitive efficiency (Maier
& Watkins, 1998).
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Figure 2. Complex interconnections between the central nervous system, hypothalamicpituitary axis, and immune system forming a reciprocal inhibitory feedback mechanism
that mediates various physiological and behavioural responses.

Note. Solid line = stimulatory effect, Dotted line = inhibitory effect
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As proinflammatory receptors tend to be concentrated within the same brain
regions responsible for regulating HPA axis responses, immune activation leads to the
cascade production of corticotropin-releasing factor (CRF), adrenocorticotropic hormone
(ACTH), and glucocorticoids. Stimulation o f the HPA axis provides a negative feedback
regulatory mechanism to suppress immune responses, preventing cytotoxic immune
reactions from getting out of control and causing excessive tissue damage (Decker,
Schondorf, Bidlingmaier, Himer, & von Ruecker, 1996; Elenkov, Papanicolaon, Wilder,
& Chrousos, 1996; Marshall et al., 1998). Elevations of various HPA molecules have
been associated with modulation of several components of immune responses, including
suppression of T-cells, macrophages, and NK cells’ function (e.g., Homo-Delarche et al.,
1991; Nair, Saravolatz, & Schwartz, 1995; Pawlikowski, Zelazowski, Dohler, & Stepien,
1988) and down-regulating gene transcription and mRNA translation of cytokines (e.g.,
Bateman, Singh, Krai, & Solomon, 1989; Cupps & Fauci, 1982; Joyce, Steer, &
Abraham, 1997; Munck, Guyre, & Holbrook, 1984; Vacca et al., 1992).

Stress-initiated responses. Alternatively, the HPA axis may be initially stimulated
in the presence of acute physical or psychological stressors. Activation of brain regions
signals the increased production of HPA molecules. The release of glucocorticoids into
the bloodstream triggers mobilization of energy sources necessary to respond to the
stress, including elevating glucose availability, increasing cardiovascular tone, and
enhancing cognition, while limiting other activities such as growth, reproduction,
digestion, and immune responses (Alderson & Novak, 2002; Brooke & Sapolsky, 2000).
Following the acute onset of a stressful situation, the neuroendocrine system can become
sensitized in order to facilitate any subsequent responses to stressors. However,
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prolonged exaggerated stress may result in the opposite effect, habituation and decreased
reactivity o f the HPA axis (Alderson & Novak, 2002; McEwen & Stellar, 1993). Chronic
dysregulation of the HPA system may result in reduced appetite, weight loss, lethargy,
weakness, gastrointestinal difficulties, and cognitive impairment (Baxter & Tyrell, 1994).
Recent evidence suggests that cytokines and HPA axis hormones may also
influence neurotransmitter systems within the brain (for review see Muller & Ackenheil,
1998; Wichers & Maes, 2002). In acute stress situations, both the HPA axis and
noradrenergic (NE) systems are initially activated. Subsequent activation of the
serotonergic (5-HT) system inhibits these circuits and reduces the stress response.
However, prolonged stress may contribute to dysregulation of the HPA axis and
imbalanced interactions between NE (hyperactive) and 5-HT (hypoactive) (Ressler &
Nemeroff, 2000). Proinflammatory cytokines can further influence neurotransmission by
altering the degradation of tryptophan, a precursor to 5-HT. Overstimulation of
indoleamine 2,3-dioxygenase (IDO), the enzyme responsible for breaking down
tryptophan, by cytokines leads to depletion of plasma concentrations of tryptophan and
ultimately a reduction in the synthesis of 5-HT in the brain (Heyes et al., 1992). The
disturbances in neurotransmitters accompanying cytokine/HPA activation may further
increase an individual’s susceptibility to develop depression and declines in cognitive
functioning (Widner, Laich, Spemer-Unterweger, Ledochowski, & Fuchs, 2002).
In summary, the intricate connections between cytokine and endocrine
messengers, perhaps mediated through alterations in neurotransmitter systems, forms a
reciprocal negative feedback mechanism that initiates and controls a wide variety of
physiological and behavioural responses. Although transient elevations in cytokines and
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hormones are adaptive in managing acute infection or responding to physical and
psychological stressors, chronic elevations or deficiencies due to significant disruptions
to immune, neural, and/or endocrine activities in certain disease states may disrupt the
structural and functional integrity of the other systems and consequently lead to
prolongation or exacerbation of certain “illness behaviours” (Brooke & Sapolsky, 2000;
McEwen, 2000).
Investigations o f biological correlates o f fatigue, cognitive symptoms, and depression in
healthy controls, medical illnesses, and mood disorders
The pattern o f physiological, behavioural, and cognitive alterations associated
with

dysregulation

of proinflammatory

cytokine/HPA/neurotransmitter processes

resembles some of the symptoms accompanying various immune-mediated illnesses,
including those commonly seen in HTV/AIDS. Although cytokine and immune alterations
have been implicated in the manifestations of many medical conditions and major
depression (Malek-Ahmadi, 1996), their relation to the pathogenesis underlying specific

symptoms remains to be elucidated. Some preliminary studies have begun to explore the
links between systemic biological indicators, fatigue (see Table 1), and cognitive status
(see Table 2) in healthy individuals and in patients with various medical conditions.
Moreover, new findings support the hypothesis that some individuals suffering from
major depression may exhibit alterations in their inflammatory responses (see Table 3)
and successful treatment with antidepressants may exert immunoregulatory effects (see
Table 4).
Results from the following studies suggest that systemic immune and endocrine

markers may provide a useful means to monitor biological changes and to investigate
their association with overall disease processes as well as with specific mood, somatic,
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and cognitive symptoms. While diverse methodological approaches and sample .
characteristics limits the direct comparison of research findings, studies measuring group
differences (e.g., mean levels of biological markers in cancer patients with and without
depressive symptoms), more so than associations (e.g., correlations between biological
markers and the severity o f depressive symptoms in cancer patients), have demonstrated
links between elevated clinical symptoms and some biological indicators. In particular,
fatigue and depressive symptoms were most consistently associated with elevated serum
levels of IL-6, TNF-alpha, and neopterin. Although only a few studies have examined the
association between cytokine profiles and cognitive symptoms, preliminary findings
suggest that IL-6 (and TNF-alpha to a lesser extent) may be useful markers in this regard.
Many studies have also documented associations between serum cortisol levels
(especially under experimental manipulations), depression, and impaired cognitive
functioning.

Healthy adults with immune/HPA activation elicited under experimental
conditions. Recent studies from groups in Germany have explored the links between
systemic biological indicators (various proinflammatory cytokines and HPA products)
and alterations in cognitive, somatic, and mood symptoms in healthy controls. SpathSchwalbe et al. (1998) examined the effects of systemically administering low doses of
IL-6 on mood, sleep, and cognitive symptoms in 16 healthy men. Prolonged increases in
plasma concentrations o f ACTH and cortisol and a mild rise in body temperature
accompanied the induced elevations in IL-6. In comparison with a placebo group, the
participants receiving IL-6 subjectively reported more fatigue and trouble with
concentrating. Sleep patterns were significantly altered with decreased rapid eye
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movements apparent throughout the night. In sleep-deprived (otherwise healthy) males,
Vgotzas (1999) also noted that elevated levels of IL-6 corresponded with measures of
daytime fatigue.
Reichenberg

et

al.

(2001)

investigated

the

cognitive

and

behavioural

consequences of inducing immune activation in a sample of twenty healthy male
volunteers. Elevations in plasma levels of TNF-alpha, TNF-alpha receptors, IL-6, and
cortisol levels were reported following the injection of an endotoxin {Salmonella abortus

equi). Despite limited changes in participants’ subjective rating of physical illness
symptoms, elevations

in TNF-alpha and cortisol plasma concentrations were

accompanied by transient increases in anxiety and depressed mood, as well as decreased
performance on measures of verbal and nonverbal memory.
Impaired learning and memory (particularly paragraph and word list recall tasks)
have also been consistently documented in healthy individuals exposed to experimental
conditions designed to elevate their cortisol levels (e.g., Newcomer, Craft, Hershey,
Askins, & Bardgett, 1994; Vedhara, Hyde, Gilchrist, Tytherleight, & Plummer, 2000;
Wolf, Schommer, Hellhammer, McEwen, & Kirschbaum, 2001). For example,
Kirschbaum, Wolf, May, Wippich, and Hellhammer (1996) examined memory
performance in conjunction with changes in cortisol levels in two separate samples of
healthy individuals. In their first experiment, 13 participants were subjected to a
psychological stressor that involved delivering a speech and performing mental math
activities in front of an audience. Participants with higher cortisol responses to the
stressor performed worse on a word list recall task. In their second experiment, 40
participants were orally given either 10 mg cortisol or placebo pills, and then tested about

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

18
an hour later on explicit verbal learning (i.e., eued-recall), implicit verbal learning (i.e.,
primed word stem completion), and spatial memory tasks (i.e., spatial locations of objects
or directions along a path). As compared to those in the placebo group, the participants
who were administered the cortisol recalled fewer words during cued-recall and made
more errors on the spatial tasks, though no difference in performance was noted across
groups for the stem-completion exercise.
Brief single dose treatment may not completely reflect the elevated cortisol levels
typically associated with stressful conditions. Newcomer et al. (1999) examined the
effects of prolonged durations of hypercorticolemia in healthy volunteers. Administration
of cortisol supplements to mimic doses associated with physical and psychological stress
over longer periods (4 days) in healthy adults also resulted in poorer recall on a verbal
paragraph learning test.
Medical conditions. Elevated levels of proinflammatory cytokines and markers of
immune activation (e.g., neopterin) have routinely been used to gauge overall disease

progression in various immune-mediated diseases, such as systemic lupus erythematosus
(SLE), cancer, Sjogren’s syndrome, arthritis, chronic fatigue syndrome, and multiple
sclerosis (MS) (e.g., Andrys, Rrejsek, Slezak, Drahosova, & Kopecky, 1999; Altingdag,
Sahin, Isimer, Akpek, & Kansu, 1999; Giovannoni et al., 1997; Maimone, Gregory,
Amason, & Reder, 1991; Sorensen, 1999; Rentzos et al., 1996; Widner et al., 1999).
More recently, studies have begun to explore possible relations between immune
mediators and specific somatic, depressive, and cognitive symptoms in some of these
immune-based medical conditions.
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Kurzrock (2001) reviewed possible behavioural implications of proinflammatory
cytokines (e.g., anemia, weight loss, night sweats, and pain) that may contribute to
cancer-related fatigue. Bower, Ganz, Aziz, and Fahey (2002) reported elevated serum
levels of TNF receptors and neopterin, as well as lower serum levels of cortisol in breast
cancer 5-year survivors with fatigue as compared with survivors without complaints of
fatigue. Acute cancer patients with fatigue prior to commencing radiation treatment had
higher IL-6 levels and immune cell counts than acute cancer patients without fatigue
(Wratten et al., 2004). In contrast, some studies on radiation-induced fatigue in cancer
patients have failed to find associations between levels of fatigue and changes (post
treatment versus baseline) in proinflammatory cytokine levels with radiation (e.g.,
Ahlberg, Ekman, & Gaston-Johansson, 2004; Geinitz et al., 2001). Discrepant findings
may, in part, reflect the diversity of cancer types, disease stages, treatment approaches,
and measures.
Elevations in proinflammatory cytokines (TNF-alpha, IL-1, and IL-6) and
occasionally cortisol levels have also been associated in some studies of fatigue in
individuals with sleep apnea (Vgontzas et al., 2000), acute coronary disease recovering
from surgery (Appels, 1999), multiple sclerosis (e.g., Flachenecker et al., 2004), and
chronic fatigue syndrome (Buchwald et al., 1997; Cleare et al., 2004; Mullington, JinzeSelch, & Pollmacher, 2001; Patarca, 2001).
Cytokine-induced behavioural changes also resemble some of the vegetative
symptoms associated with depression, including anorexia, weight loss, psychomotor
retardation, sleep disturbances, and anergy (Maes, 1993). Musselman et al. (2001)
compared plasma concentrations of IL-6 and cortisol levels following dexamethasone
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suppression in a group of cancer patients diagnosed with or without comorbid depression.
The cancer patients with major depression (n = 8) had markedly higher plasma IL-6
levels than cancer patients without major depression (n = 13) and healthy controls (n =
10). Scores on the depression measure (Hamilton Depression Rating Scale) were
positively correlated with cortisol levels, though no association was evident for IL-6
plasma levels. Similarly, elevations in plasma IL-6 concentrations have been described in
depressed patients with rheumatoid arthritis (RA) as compared with non-depressed
controls without RA or RA patients without depression (Zautra et al., 2004).
Kahl, Kruse, Fahler, Weiss, and Reickmann (2002) examined the association
between mRNA TNF-alpha levels, depressive symptoms, and disability status in a group
of recently diagnosed patients with MS (n = 16) and demographically matched healthy
controls. MS patients demonstrated higher TNF-alpha mRNA expression and depressive
symptoms than controls. Depressive symptoms, but not disability status, was positively
correlated with TNF-alpha expression both at baseline and 3 to 6 months later.
Although increased levels of proinflammatory cytokines have commonly been
reported in multiple sclerosis, fibromyalgia and chronic hepatitis C infection, some
studies have failed to find consistent associations between symptom measures of fatigue
or depression and systemic markers of inflammatory disease activity (e.g., Gershon,
Margulies, Gorczynski, & Heathcote, 2000; Giovannoni, Thompson, Miller, &
Thompson, 2001; Gur et al., 2002). However, the majority of these studies examined
associations between symptom severity within a single patient group rather than the
aforementioned studies that compare conditions with control groups.
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Adults with chronic glucocorticoid elevations or deficiencies often demonstrate
cognitive impairments, in particular on certain types of learning and memory tasks.
Difficulties on explicit memory tasks (e.g., word list or paragraph recall) have been
observed in individuals with rheumatoid arthritis who were administered prolonged doses
of exogenous glucocorticoids like prednisone (Keenan, Jacobson, Soleymani, &
Newcomer, 1995; Keenan et al., 1996). Elevated cortisol levels in patients with
depression were positively correlated with problems on tests of verbal memory (Sheline,
Wang, Gado, Csemansky, & Vannier, 1996; van Londen et al., 1998). Higher cortisol
levels in Alzheimer disease patients were associated with poorer performance on
cognitive screening measures (Rasmuson et al., 2001; Umegaki et al., 2000; Weiner,
Vobach, Olsson, Svetlik, & Risser, 1997). Moreover, individuals with Cushing’s disease
often experience cognitive problems and reductions in plasma cortisol levels following
treatment has led to some improvements in cognitive functioning, especially on verbal
paired-associate learning and recall tasks (Mauri et al., 1993; Starkman et al., 1992).
Much less research is available on the specific cognitive changes mediated by
cytokines. Kozora et al. (2001) examined the contribution of IL-6, cortisol, and
dehydroepiandrosterone (DHEA) to cognitive impairments in 15 individuals with SLE
and 15 individuals with RA. In comparison with 15 age-matched controls, SLE and RA
patients performed significantly worse than controls on measures of attention, and SLE
patients performed significantly worse than RA and controls on measures of list,
paragraph, and figure recall. Cognitive impairments, especially in SLE group, were
associated with abnormal levels of DHEA and IL-6 but not cortisol even after controlling
for potentially confounding factors such as depression and corticosteroid treatment.
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Weaver et al. (2002) investigated the relation between plasma IL-6 and risk for
cognitive decline in a sample of 779 elderly men and women. Higher baseline levels of
IL-6 were marginally associated with poorer baseline cognitive functioning even after
controlling for various demographic, social, and health variables. Individuals with higher
baseline levels of IL-6 were also more likely to exhibit cognitive declines at follow-up 2

Vz and 7 years later. In a similar prospective study enrolling 3031 older adults, Yaffe et
al. (2003) reported associations between elevated baseline serum IL-6 and cognitive
decline at 2-years follow-up. The authors suggested that serum markers of immune
activation may provide a practical means to monitor and predict older individuals at-risk
for cognitive decline. Recently, Mantovani et al. (2004) examined the significance of
serum IL-6 elevations in older adults with cancer. While higher IL-6 was not directly
associated with general measures of cognitive status, IL-6 levels did correlate with
measures of functional activities of daily living.

Mood disorders. Evidence has recently emerged suggesting that major depression
may be accompanied by moderate immune activation. Maes and colleagues (1993, 1995)
reported an increase in the plasma concentration and in vitro production of IL-1 and IL-6
in patients with Major Depressive Disorder (MDD) in comparison with non-depressed
controls. They indicated that increased levels of proinflammatory cytokines correlated
with severity of the depressive illness, elevated cortisol, and decreased tryptophan levels.
The vast majority o f studies reviewed similarly found elevations in plasma concentrations
of proinflammatory cytokines (in particular IL-6) in individuals with MDD, dysthymia,
and seasonal affective disorder (e.g., Leu, Shiah, Yatham, Cheu, & Lam, 2001; Penninx
et al., 2003; Schlatter, Ortuno, & Cervera-Enguix, 2004; Sluzewska et al., 1996; Suarez,
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Ranga, Krishnan, & Lewis, 2003; Trzonkowski et al., 2004). Elevated indicators of cellmediated immunity, including increased monocyte counts and production of neopterin,
have also been observed in depressed individuals (e.g., Bonaccorso et al., 1998; Dunbar
et al., 1992; Maes et al., 1994).
Selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressant (TCA)
medications have shown immunosuppressant effects both in vivo and in vitro (for review
see Maes, 2001). Animal models have demonstrated inhibitory influences of SSRIs on
the production of acute phase proteins and proinflammatory cytokines (Song & Leonard,
1994). An in vitro study conducted by Xia, DePierre, and Nassberger (1996) found that
various SSRIs and TCAs inhibited proinflammatory cytokine release in samples of
stimulated human blood monocytes. However, Kubera et al. (2004) noted that patients
with treatment-resistant depression showed increased production o f IL-6 in their blood
cell samples when antidepressants were added. Prolonged treatment with SSRIs has lead
to normalization of serum IL-6 levels in depressed patients relative to controls
(Frommberger et al., 1997; Sluzewska et al., 1995). However, many studies have not
observed corresponding changes in proinflammatory cytokine levels with short-term
antidepressant treatment (e.g., Brambilla et al., 1998; Kubera et al., 2000; Mikova et al.,
2001). Study methodology, severity and chronicity o f the mood disturbance, durations of
therapeutic doses, types of antidepressants, and individuals differences in response to
antidepressant treatment may account for some of the discrepant findings. Interestingly,
Lanquillon et al. (2000) reported that higher TNF-alpha production by blood
mononuclear cells was reduced after a 6-week treatment with amitriptyline in treatment
responders, but not in individuals unresponsive to the antidepressant treatment.
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Table 1

Selected studies comparing the link between fatigue and biological markers
1st Author (year)
Ahlberg (2004)

Appels (1999)

Bower (2002)

Buchwald (1997)

Cannon (1999)

Cleare (2004)

Flachenecker (2004)

Geinitz (2001)

Gershon (2000)

Sample
Women with uterine cancer
undergoing radiation therapy
(baseline, 3 wks & after
treatment)
Acute coronary disease patients
with fatigue cf. patients without
fatigue
Breast cancer 5-year survivors
with fatigue cf. patients without
fatigue

NTa

Ncb

Measure
Multidimensional Fatigue
Inventory

15

Lab markers0

Group0

ns

15

15

Self-report exhaustion

IL-1 (s)
TNF-alpha (s)

f
f

20

20

RAND 36-item Health Survey:
Energy/ Fatigue subscale

TNF-receptors (s)
IL-1 receptor (s)
Neopterin (s)
Cortisol (s)

t
f
f

CRP (s)
Neopterin (s)
IL-6
Basal IL-6 (s)
A IL-6 (s)

t

Individuals with chronic fatigue
cf. standard clinical range

153

Individuals diagnosed with
chronic fatigue syndrome cf.
controls
Individuals with chronic fatigue
syndrome without depression cf.
controls
Multiple sclerosis patients with
fatigue cf. patients without
fatigue
Breast cancer patients during the
course o f radiation therapy
(baseline & 2 months post)
Adults diagnosed with Chronic
Hepatitis C

6

4

16

16

26

14

41

78

41

Self-report exertion after 15
minutes exercise

Krupp’s Fatigue Severity Scale

Fatigue Assessment Questionnaire
& Visual Analog Scale on Fatigue
Intensity
Fatigue Severity Score

re
ns

AIL-1 (s)
A IL-6 (s)
A TNF-alpha (s)

t
ns

t
ns

DHEA (s)
Cortisol (s)

t
f

IFN-gamma (mRNA)
TNF-alpha (mRNA)
IL-10 (mRNA)
A IL-1 (s)
A IL-6 (s)
A TNF-alpha (s)
IL-1 (s)
IL-6 (s)
TNF-alpha (s)

ns

ns
ns

t
ns
ns
ns
ns
ns
ns
ns
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Giovannoni (2001)

Multiple sclerosis patients

38

Fatigue Questionnaire Scale &
Krupp’s Fatigue Severity Scale

Neopterin (u)
CRP (s)

ns

Omdal (2002)

Patients with systemic lupus
erythematosus

5

Fatigue Severity Scale

ns
ns
ns
ns

Patarca (1994)

Patients with chronic fatigue
syndrome cf. standard clinical
ranges

70

IL-2 (s)
IL-6 (s)
IL-10 (s)
TNF-alpha (s)
TNF-alpha (s)
TNF-beta (s)
IL-1 (s)
IL-2 (s)
IL-2 receptor (s)
Neopterin (s)

Spath-Schwalbe
(1998)

Healthy men administered lowdose IL-6 cf. placebo

16

Vgontzas (1999)

Healthy males in sleep
deprivation experiment
Men with sleep apnea cf.
nonapneic matched controls
Patients with fibromyalgia with
fatigue cf, controls

8

Vgontzas (2000)
Wallace (2001)

16

Self-report fatigue & REM sleep

IL-6 (s)
ACTH (s)
Cortisol (s)
IL-6 (s)

14

23

56

56

Amount and depth of sleep at baseline
Daytime sleepiness and fatigue
Sleep disturbance & daytime
sleepiness
Self-report fatigue

t
t
t
t
t
t
t
t
t

+
+
+

.
+

TNF-alpha (s)
IL-6 (s)
IL-1 receptor (s)
IL-8 (s)
IL-6 (stim)

t
t
t
t
t
f

+
IL-6 (s)
Functional Assessment o f Cancer
21
28
Acute cancer patients starting
Therapy
radiation therapy with fatigue cf.
patients without fatigue
Note, 8NT= sample size for treatment or condition group; t’Nc = sample size for control group, cIL=interleukin, TNF=tumor necrosis factor, IFN = interferon,
ACTH = adrenocorticotropic hormone, CRP = C-reactive protein, s = serum levels, u = urinary levels, mRNA- levels o f mRNA expression, stim = levels
following stimulation ofPBM Cs with mitogen (LPS/PHA), A = change in marker over time; d t = elevated levels in condition versus control group, I = lower
levels in condition versus control group, ns = non-significant difference between condition and control;e + = significant positive correlation (i.e., increased
fatigue associated with elevated level o f marker), - = significant negative correlation (i.e., increased fatigue associated with low level o f marker), ns = non
significant
Wratten (2004)

to
Ul
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Table 2

Selected studies comparing the link between cognitive function and biological markers
1st Author (year)

Sample

Errico (2002)

Alcoholic males during
early withdrawal

Keenan (1995)

Patients with rheumatoid
arthritis on prolonged
prednisone treatment cf.
patients with no treatment
Healthy participants
exposed to psychosocial
stressor (Trier Social Stress
Test)
Healthy participants
administered cortisol cf.
placebo

Kirschbaum (1996):
Experiment 1

N /
18

Ncb

25

25

13

20

20

Patients with Systemic
Lupus Erythematosus cf.
matched-controls

15

15

Lupien (1999)

Healthy men with varying
doses of hydrocortisone cf.
placebo

30

Mantovani (2004)

Older adults with cancer

84

Mauri (1993)

Cushing’s syndrome
patients cf. matched controls

25

Kirschbaum (1996):
Experiment 2

Kozora (2001)

10

25

Measures

Lab markers0

1. Verbal Memory (Story recall)
2. Cognitive Flexibility (Wisconsin Card
Sorting Test)
1. Verbal Memory (Paragraph recall)
2. Non-declarative Memory (Word-stem
priming)

f Cortisol (s)

Verbal Memory (Recall o f 26-item word
list)

t Cortisol (o)

1. Verbal Declarative Memory (Cued
recall word list)
2. Spatial Memory (park pathway & bam
location)
3. Procedural Memory (Word-stem
completion task)
Learning Index (Immediate Story Recall,
Immediate Figure Recall, & Word List
Learning) and Attention Index (Digit
Vigilance Test & Paced Auditory Serial
Addition Test)
1. Working Memory (Item-Recognition
Task)
2. Verbal Declarative Memory (Recall of
Word Pairs)
1. Cognitive Status
2. Functional Activities of Daily Living
Verbal Memory (Paragraph recall &
Paired associates learning tasks)

T Cortisol (s)

t Cortisol (s)

Groupd

1. 4
2. ns

1. 4
2. 43. ns

i IL-6 (s)
•I DHEA (s)

+
ns

ns Cortisol (s)

t Cortisol (s)

1. i
2. ns

ns

f IL-6 (s)
tC ortisol (s)

Assoc®
1. 2. -

4’

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Newcomer (1994)
Newcomer (1999)

Rasmuson (2001)

Reichenberg (2001)

Sheline (1996)
Spath-Schwalbe
(1998)
Starkman (1992)
Umegaki (2000)

Van Londen (1998)
Vedhara (2000)

Healthy adults administered
dexamethasone cf. placebo
Healthy participants
administered low and high
doses o f cortisol for 4 days
cf. placebo group
Women with Alzheimer
disease c f young & older
healthy women
Healthy males injected with
an endotoxin cf. placebo
Depressed patients cf.
matched controls
Healthy men administered
low-dose IL-6 cf. placebo
Cushing’s syndrome
patients
Patients with Alzheimer
disease and vascular
dementia cf. control elderly
Depressed patients cf. non
depressed controls
Students during exam
periods cf. students during
non-exam periods

Weaver (2002)

Older adults

Weiner (1997)

Patients with Alzheimer
disease

10

9

31

20

10

20

Verbal Memory (Immediate & Delayed
Paragraph Recall)
Verbal Memory (Immediate and Delayed
Paragraph Recall)

i Cortisol (o,
dex supp)
t Cortisol (s)

14

Clinical Dementia Rating Scale

t Cortisol
metabolites (u)

20

t TNF-alpha (s)
t Cortisol (s)
f IL-6 (s)
TCortisol(s)

10

10

16

16

Verbal Memory (Story Recall & List
Learning) and Visual Memory (Figure
Recall)
Verbal Memory (Paragraph recall & List
learning)
Self-report difficulties with concentration

94

21

Verbal Memory (Paragraph recall &
Paired Associates Learning tasks)
Mini Mental Status Examination

15

15

60

60

12

779

9

Verbal Memory (Paragraph recall & List
learning)
1. Attention (Test of Everyday Attention)
2. Verbal Memory (Primacy Effect for
20-item Word List)
3. Verbal Memory (Immediate Recall)
Modified Mini Mental Status
Examination (Cognitive status at 2Vz and
7 yrs follow-up)
Modified Alzheimer Disease Assessment
Scale-Cognitive (Change score from
baseline to 2.5 years)

t
t
t
t

4
4

I

ns

+

IL-6 (s)
ACTH (s)
Cortisol (s)
Cortisol (s)

»

TCortisol (s)

t Cortisol (s)
4- Cortisol (o)

4
1. +
2. +
3 .-

T IL-6 (s) at
baseline
TCortisol (s):
baseline

+

to

<1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Widner (2000)

W olf (2001)

Wolkowitz (1990)

Patients with Alzheimer
disease cf. similar aged
controls
Healthy participants
exposed to psychosocial
stressor (Trier Social Stress
Test) cf. controls

21

20

Mini Mental Status Examination

I Tryptophan (s)

22

36

Verbal Learning (Immediate Recall of
Word List)

t Cortisol (o):
men
t Cortisol (o):
women

Depressed patients

21

Verbal Memory (Word list recognition
task)

tC ortisol (s, dex
supp)

+

ns
ns

At Baseline:
t IL-6 (s)
f CRP (s)
t TNF-alpha (s)
Note. aNT= sample size for treatment or condition group; “TSfc ~ sample size for control group; cIL=interleukin, TNF=tumor necrosis factor, ACTH ~
adrenocorticotropic hormone, DHEA = dehydroepiandrosterone, CRP = C-reactive protein, s = serum levels, o = saliva levels, dex sup= serum levels under
conditions o f dexamethasone suppression, t = elevated levels, I = low levels;* t = poorer performance on test in condition versus control group, ns = no
difference between condition and control performance;f + = positive correlation between performance and serum levels, - = negative correlation between
performance and serum levels, ns = association not significant
Yaffe (2003)

Older adults

3031

ns

Modified Mini Mental Status
Examination
(Cognitive status at 2-year follow-up)

ns

SJ

00
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Table 3

Selected studies comparing the link between depression and biological markers
1st Author (year)
Anisman (3999)

Appels (2000)

Bonaccorso (1998)
Brambilla (1998)

Carpenter (2004)
Frommberger (1997)

Glaser (2003)
Gur (2002)

Gur (2004)

Sample3
Patients with MDD or
dysthymia cf. non-depressed
controls

Patients with coronary artery
disease with depressive
symptoms/exhaustion cf.
patients without depressive
symptoms/exhaustion
Patients with MDD c f normal
controls
Elderly women with MDD
(inpatients) c f matched
controls
Patients with MDD cf.
matched controls
Patients with MDD cf. healthy
controls
(*acute MDD vs. **MDD in
remission)
Older adults

NTb
27

Ncc
27

Diagnosisd

15

15

10

17

DSM-IIIR

10

20

DSM-IIIR

26

DSM-IV

12

12

DSM-IIIR

Patients with Fibromyalgia
and depressive symptoms cf.
healthy controls

81

Patients with fibromyalgia
(FM) and chronic fatigue
syndrome cf. healthy controls

130

32

46

Lab markers®
IL-1 (stim)
IL-2 (stim)
ACTH (s)
Cortisol (s)
NE (s)

Group
f
1
t

IL-1 (mRNA)
TNF-alpha (mRNA)

Neopterin (u)

t

Hamilton Depressing
Rating Scale

IL-1 (s)
IL-6 (s)
TNF-alpha (s)
IL-6 (csf)

ns
ns
ns
ns

Montgomery Asberg
Depression Rating

IL-6 (s)

Beck Depression
Inventory
Hamilton Depression
Rating Scale

IL-6 (s)

Beck Depression
Inventory

IL-1 (s)
IL-2 receptor (s)
IL-6 (s)
IL-8 (s)
Cortisol (s)

r8

I
f
t
t

Self-report
depression/
exhaustion

18

119

Measure

DSM-IIIR/
DSM-IV

ns
ns
ns

f (*)
ns (**)
+
ns

f
ns

f
4
(esp
FM)
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Kahl (2002)

Leu (2001)

Maes (1995)

Maes (1997)

Mikova(2001)

Musselman (2001)

Natelson (1999)

Multiple sclerosis patients cf.
healthy controls

Patients with Seasonal
Affective Disorder cf,
matched normal controls
Patients with MDD (acute and
chronic remission) cf. healthy
controls
Patients with MDD (including
treatment-resistant depression)
cf. non-depressed controls
Patients with MDD cf.
controls

Cancer patients with comorbid
MDD cf. cancer patients
without depression
Patients with chronic fatigue
syndrome and comorbid MDD
cf. healthy controls

16

Beck Depression
Inventory

10

TNF-alpha (mRNA)
INF-gamma (mRNA)
IL-10 (mRNA)
IL-4 (mRNA)

t
t
t
ns

IL-6 (s)
IL-6 receptor (s)
IL-2 receptor (s)
IL-6 (s)
IL-6 receptor (s)
IL-2 receptor (s)

f
OS

15

15

77

38

DSM-IIIR

Hamilton Depression
Rating Scale

35

15

DSM-IIIR

Hamilton Depression
Rating Scale

IL-1 receptor (s)
Il-6(s)

ns
t
t
t
t
t

28

15

DSM-IV

8

13

DSM-IIIR

Hamilton Depression
Rating Scale

IL-6 (s)
IL-8 (s)
TNF-alpha (s)
IL-2 receptors (s)
IL-6 (s)
Cortisol (s, dex sup)

t
ns
t
ns
t
t

IL-1 (mRNA)
IFN-gamma (mRNA)
IL-2 (mRNA)
IL-4 (mRNA)
IL-6 (mRNA)
IL-10 (mRNA)
IL-12 (mRNA)
TNF-alpha (mRNA)
IL-6 (s)
TNF-alpha (s)
CRP (s)
TNF-alpha (s)
Cortisol (s)
IL-6 (s)

4
ns
ns
ns
ns
ns
ns
ns
t
t
t

30

87

2879

Penninx (2003)

Elderly adults with depressive
symptoms cf. normal controls

145

Reichenberg (2001)

Healthy males injected with an
endotoxin

20

DSM-IIIR

Centers for
Epidemiological
Study-Depression

Centers for
Epidemiological
Study-Depression
Depression
Adjectives Check
List

+
4~

ns

ns
ns

ns
4*

4~

+
4~
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Schlatter (2004)

Patients with MDD or
dysthymia cf. healthy controls

22

Sluzewska(1996)

Inpatients with MDD cf. non
depressed controls

49

Starkman (1992)

Patients with Cushing’s
disease
Non-smoking healthy men

11

Suarez (2003)

Trzonkowski (2004)

Elderly with MDD cf. non
depressed controls

15

15

DSM-IIIR

DSM-IIIR

53

10

10

DSM-IV

T

IL-1 (stim)
IL-6 (stim)
TNF-alpha (stim)

ns

Hamilton Depression
Rating Scale

IL-6 (s)
IL-6 receptor (s)
IL-2 (s)
CRP (s)

t
t
t
t

Hamilton Depression
Rating Scale
Beck Depression
Inventory

ACTH (s, dex sup)

Hamilton Depression
Rating Scale

IL-1 (stim)
TNF-alpha (stim)
IL-8 (stim)
TNF-alpha (s)
IL-6 (s)
ACTH (s)
Cortisol (s)

t

ns
ns
ns

ns
ns
ns
ns
+
4-

+
4-

t
t
4
t

ns
Beck Depression
Cortisol (s)
Individuals with rheumatoid
33
4Prolactin (s)
Inventory
arthritis
_
.
DSM-IV
IL-6 (s)
106
45
Rheumatoid arthritis (RA)
Zautra (2004)
patients with comorbid MDD
cf. RA patients without
depression and healthy
controls
Note.a MDD=major depressive disorder; "Nr = sample size for treatment or condition group; CNC= sample size for control group,
dD S M = Diagnostic and Statistical Manual of Mental Disorders; eIL=interleukin, TNF=tumor necrosis factor, ACTH = adrenocorticotropic hormone, CRP = Creactive protein, IFN = interferon, NE = norepinephrine, s = serum levels, csf= cerebral spinal fluid levels, u = urinary levels, dex sup= serum levels under conditions of
dexamethasone suppression, mRNA= levels o f mRNA expression, stim = levels following stimulation ofPBM Cs with mitogen (LPS/PHA); f t = elevated levels in
condition versus control group, I ~ lower levels in condition versus control group, ns = non-significant difference between condition and control groups;g + =
significant positive correlation (i.e., increased severity o f depression associated with elevated level o f marker), - = significant negative correlation (i.e., increased
severity of depression associated with low level o f marker), ns = non-significant
Zautra (1994)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 4

Selected studies investigating the effects o f antidepressants on biological indicators
1st Author (year)
Sample3
Treatment
Duration
NTb Ncc
Brambilla (1998)

Elderly women with MDD
(inpatients) cf. matched controls

10

20

Phosphatidylserine

30 days

Kubera (2000)

Patients with M DD cf. non
depressed controls

9

10

Unspecified antidepressants

6 weeks

Kubera (2004)

Treatment-resistant depressed
patients cf. controls
Inpatients with MDD cf. controls
(*non-responders **responders)

7

19

Imipramne, venlafaxine, L-5-HT,
or fluoxetine
Amitryptiline

Lanquillon (2000)

24

6 weeks

Lab markers
IL-1 (s)
IL-6 (s)
TNF-alpha (s)
IL-1 receptor (s)
IL-6 (s)
IL-10 (s)

Patients with MDD (acute and
chronic remission) cf. healthy
controls

77

38

Mixed sample (fluoxetine,
nortiptyline, amitryptiline, or
imipramine)

81.2+/-38.3
days

IL-6 (s)
IL-6 receptor (s)
IL-2 receptor (s)

Maes (1997)

Patients with MDD (including
treatment-resistant depression) cf.
non-depressed controls

35

15

Trazodone alone, Trazadone with
pindolol or Trazadone with
fluoxetine

5 weeks

IL-1 receptor (s)
IL-6(s)
IL-6 receptor (s)

Maes (1999)

Normal healthy adults

9

Mikova (2001)

Patients with MDD cf. controls

14

Weizman (1994)

Patients with M DD cf, matched
healthy controls

10

X ia e ta l. (1996)

Normal healthy adults

4

15

10

Mixed sample (clomipramine,
paroxetine, mianserin, or
amitriptyline)
Clomipramine

Clomipramine, imipramine or
citalopram

6 weeks

4 weeks

ns

IL-6 (s)
IL-8 (s)
TNF-alpha (s)
IL-2 receptors (s)

ns

t
ns

ns

i(**)
ns
ns
ns
ns
ns

I
ns
ns
ns
ns

t
t
t
4
4
4
4

IL-1 (stim)
IL-2 (stim)
IL-3 (stim)
IL-2 (stim)
IFN-gamma (stim)
TNF-alpha (stim)
IL-6 (stim)
_i.:_
... . d r r :

ns
ns
ns
ns
ns
ns

T(*)
t (both)
t
t
f
t
f
t
4
t
f

IFN-gamma (stim)
IL-10 (stim)

Clomipramine, sertraline, or
trazadone

Change1

ns
ns
ns

t
t
t
t

IL-6 (stim)
TNF-alpha (stim)
IL-6 (s)
TNF-alpha (s)

Maes (1995)

Group®

t

Note. MJJU=major depressive disorder; jnt = sample size ior treatment or condition group; rsc - sampie size tor control group, uu-uucucwuu, r i>r—tumoi
factor, IF N - interferon, s = serum levels, stim —levels following stimulation o f PBMCs with mitogen (LPS/PHA);6 T = elevated levels in condition versus control
group, 4 * lower levels in condition versus control group, ns = non-significant difference between condition and control group;f 4 = reduced levels over time with
treatment, ns *=no significant changes in levels over time with treatment

N3

33
Potential neural correlates o f “illness behaviour”
Given the higher density of proinflammatory cytokine and hormonal receptors
located within the hypothalamus, hippocampus, basal ganglia, and prefrontal cortex
connections, functions of these brain regions may be more susceptible to cytokine/HP Ainduced activity. For brevity and readability the hypothesized functions of these brain
structures are reviewed, though it is recognized that these structures do not function in
isolation but rather operate as part of comprehensive pathways within the brain.
The multiple nuclei within the hypothalamus form intricate connections with
diverse regions o f the brain, including the brain stem, anterior thalamus, limbic cortex,
hippocampus, and pituitary gland. Stimulation and lesion studies have shown that the
hypothalamus is pivotal for the integrated control and maintenance of many different
physiological activities, such as regulation of arterial pressure and heart rate, body
temperature, sleep-wakefulness cycles, water conservation, hunger sensation, sexual
drive, pain perception, and emotional control (Guyton, 1991). The hypothalamus co
ordinates bodily functions in a rhythmic fashion (daily and seasonal cycles) as well as
spontaneously in response to internal and external factors (Overeem et al., 2002).
The medial temporal lobe system is comprised of the hippocampus and adjacent
cortical regions. Bidirectional projections exist between the hippocampus and entorhinal
cortex. The entorhinal cortex forms reciprocal projections with parahippocampal and
perirhinal cortices, as well as sends and receives information from orbitofrontal,
cingulate, superior temporal gyrus, and insular cortices. The parahippocampal and
perirhinal cortices have more widespread reciprocal connections with unimodal and
polymodal association areas in frontal, temporal, and parietal lobes (Squire, 1992; Squire,
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Stark, & Clark, 2004). The integrity of the hippocampus and related structures has been
linked to learning and memory. Convergent support comes from numerous lesion and
imaging studies in rats, nonhuman primates, and humans (for detailed reviews see
Eichenbaum, 1999; Lepage, Ghaffar, Nyberg, & Tulving, 2000; Squire, 1992; Squire,
Knowlton, & Musen, 1993; Squire et al., 2004; Tulving & Markowitsch, 1998). In
particular, declarative memory (also referred to as explicit, relational, contextual, or
configurational memory) that involves the formation of relationships, transfer of newly
acquired information to long-term storage, and recalling facts or events over short periods
o f time may be mediated by the medial temporal lobe system. The role of the
hippocampal structures in learning and memory storage is thought to be temporary, such
that memory gradually reorganizes so that permanent storage occurs in the neocortex
(Squire, 1992; Squire et al., 2004). Following consolidation and more permanent storage
o f new information, retrieval of this information is thought to involve extra-hippocampal
structures including the frontal cortex (Squire et al., 1993).
The ffontal-subcortical circuitry are highly complex and mediate a wide range of
behaviours and motor activity. A series of five parallel circuits linking specific regions of
the frontal cortex to the striatum, globus pallidus, and thalamus have been described (e.g.,
Alexander, DeLong, & Strick, 1987; Cummings, 1993; Tekin & Cummings, 2002). The

motor circuit, originating in the supplementary motor area, premotor cortex, and motor
cortex, is responsible for initiating and sequencing multiple successive and parallel
muscle movements to achieve desired goals. The oculomotor circuit originates from the
frontal eye field and posterior parietal cortex, and mediates the complexity o f eye
movements. The dorsolateral prefrontal circuit is thought to be involved in cognitive
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tasks, such as planning, organization, regulating behaviours, shifting sets, and solving
novel problems. Personality changes, behavioural disinhibition, and emotional lability
may result from disruption of the lateral orbitofrontal circuit. The anterior cingulate

circuit is thought to be important for motivation, such that lesions in this pathway result
in apathy, indifference, and lack of motor and verbal initiation (for detailed review see
Tekin & Cummings, 2002).
The neuropathology o f HIV: A t system, cellular, and molecular levels
Brain regions. Neuroradiology and pathology studies provide support for the
potential disruption of both medial temporal and frontal-subcortical brain systems in
HIV. Post-mortem analyses of individuals with AIDS often reveal cerebral atrophy with
sulci widening and ventricular dilation (e.g., Poutiainen et al., 1993; Vago, Trabattoni,
Lechi, Cristina, & Budka, 1990). Central white matter lesions and loss of specific
subpopulations of neurons found within the basal ganglia, hippocampus, and frontaltemporal cortex are frequently observed (e.g., Bell, 1998; Gendelman et al., 1994; Wiley
et al., 1991). For example, Reyes, Mohar, Mallory, Miller, and Masliah (1994) described
neuronal atrophy and astrogliosis of the hippocampal formation, basal ganglia, and
frontal cortex in 11 out of 19 autopsies of individuals with AIDS. High HIV viral DNA
loads were also found in the medial temporal lobe region during post-mortem analyses of
eight patients diagnosed with AIDS-related dementia (Fijumura et al., 1997). Petito,
Roberts, Cantando, Rabinstein, and Duncan (2001) recently described neuronal loss,
increased astrocyte gliosis, and the presence of high levels of cytokine co-receptors in
hippocampal regions based on autopsies of 22 adults with AIDS.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

36
Similarly, structural imaging studies have documented diffuse cerebral atrophy,
widening

cortical

sulci,

enlarged ventricles,

and periventricular white

matter

abnormalities in some individuals with HIY infection and AIDS (Elovaara et al., 1990;
Raininko et al., 1992). Oberfield et al. (1994) noted the presence of hippocampal atrophy
on 8 out o f 15 CT scans o f children with HIV infection. Decreased volume of the basal
ganglia has also been observed and correlated with increased cognitive impairments (e.g.,
Aylward et al., 1993; Aylward et al., 1995; Hestad et al., 1993). Harrison et al. (1998)
reported that the presence of white matter abnormalities on MRI scans was associated
with poor overall neuropsychological performance and more specifically, declines on
tests of executive functioning, psychomotor speed, and nonverbal memory.
Moreover, abnormal regional blood flow in temporal and frontal regions has been
documented in patients with HIV infection relative to controls using both functional
magnetic resonance imaging and positron emission tomography imaging scans (e.g.,
Chang, Ernst, Leonido-Yee, & Speck, 2000; van Gorp et al., 1992; Wiseman et al.,
1999). More marked abnormalities have been correlated with more advanced disease
stage, lower CD4 T cell counts, higher viral loads, and increased cognitive impairments
(e.g., Chang, Ernst, Leonido-Yee, & Speck, 2000; Chang et al., 2002; Hall, Whaley,
Robertson, & Hamby, 1996).

Biological mechanisms.

Progressive impairments

in immune

and CNS

functioning in individuals with HIV are thought to result from both direct and indirect
destruction of cells during the viral replication process (Gorman & Kertzner, 1990). The
HIV virus has a predilection for cells with CD4 receptors (i.e., CD4 T lymphocytes,
macrophages, and microglial cells). Macrophages are thought to be responsible for
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transporting HIV across the blood brain barrier and have been shown to enter the CNS
within days to weeks of infection (e.g., Davis et al., 1992; Resnick, Berger, Shapshak &
Tourtellotte, 1988). However, HIV does not seem to directly infect neurons or
oligodendrocytes but instead reservoirs of virus are stored within brain macrophages,
microglia, and multinucleated giant cells (e.g., Gendelman et al., 1994; Minagar et al.,
2002; Orenstein, 2001). Chronic low-grade activation of macrophages and microglia by
HIV results in the release of a cascade of neurotoxic viral (e.g., protein gpl20) and/or
cellular factors (e.g., proinflammatory cytokines, nitric oxide, oxygen radicals,
prostaglandins, or leukotrienes) that can cause secondary damage to surrounding tissue
(e.g., Brenneman, McCune, Mervis, & Hill, 1994; Gendelman et al., 1994; Minagar et al.,
2002).
Excess production of proinflammatory cytokines (most notably TNF-alpha) may
have multiple adverse effects on their own: (1) stimulate microglia and astrocytes to
produce additional neurotoxins such as arachidonic metabolites, quinolinic acid, and
nitric oxide (Genis et al., 1992; Wesselingh et al., 1994; Pemberton, Kerr, Smythe, &
Brew, 1997); (2) inhibit astrocytes from buffering extracellular glutamate which is also
neurotoxic in excess amounts (Fine et al., 1996); (3) enhance HIV infection of host cells
and viral replication processes (Alfano & Poli, 2001; Merrill & Chen, 1991; Vyakamam,
McKeating, Meager, & Beverley, 1990); and (4) stimulate production of adhesion
molecules and chemokines (MCP-1) that alter permeability of the blood brain barrier to
immune cells (Fiala et al., 1997; Nottet et al., 1996).
The HIV virus may stimulate the HPA axis directly via the production of peptide
sequences similar to pituitary regulatory hormones (e.g., ACTH) or indirectly by
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cytokines enhancing CRF secretion (Corley, 1995; Sapolsky, Rivier, Yamamoto, Plosky,
Vale, 1987; Smith & Blalock, 1982; Woloski et al., 1985). Elevated cortisol levels and
HPA axis imbalances, regardless of their aetiology, may hasten the progression of HIV
infection by suppressing cell-mediated immune functioning and the production of Type 1
cytokines (Clerici et al., 1997b; Corley, 1995; Rook, Onyebujon, & Stanford, 1993;
Sapse, 1997). Interestingly, glucocorticoids may also further exacerbate the neurotoxic
effects o f gpl20. A synergistic increase in neuronal death was apparent in cultures of
hippocampal, cortical, and striatal tissues from rats when both gpl20 and corticosterone
(similar to cortisol in humans) were present (Brooke, Chan, Howard, & Sapolsky, 1997;
Iyer, Brooke, & Sapolsky, 1998). Brooke and Sapolsky (2000) hypothesized that both
gpl20 and glucocorticoids contributed to neuronal death by altering different aspects of
cellular metabolism, and together accelerating the depletion of energy sources.
Although the exact mechanism by which HIV damages neurons is still unknown,
these findings suggest that damage to brain systems may stem from death of neurons,

disruption of neuronal functioning, and/or modification of neurotransmitter systems
(Adle-Biassette et al., 1999; Bell, 1998; Everall et al., 1999) indirectly mediated through
factors released from proximal virus-infected macrophages and microglia (Gendelman et
al., 1994; Minagar et al., 2002). Neuronal destruction may be further amplified by the
interaction and perpetuation of immune and endocrine molecules via positive feedback
loops. Central white matter and deep grey matter are often characterized by infiltration of
macrophages containing HIV virus, astrogliosis, and the development of microglial
nodules and multinuclear giant cells (i.e., fused macrophages and/or glial cells often
containing copious amounts of virus and surrounded by ineffective T cells) (Gendelman
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et al., 1994). The presence of miiltinttclear giant cells has been correlated with the degree
of dementia (McArthur et al., 1999). As outlined above, the disruption of certain brain
systems (hypothalamic, medial temporal, and frontal-subcortical) may contribute to
somatic, cognitive, and depressive symptoms in some individuals. Consequently, it may
be useful to examine whether individual differences in immune and endocrine
functioning is associated with the presence of these symptoms in HIV. The present study
selected systemic indicators reflective of different aspects of this mechanism: (1) HIV
replication and disease status (CD4 T cell counts and viral load); (2) macrophage
activation and cytotoxicity (neopterin); (3) proinflammatory cytokines (IL-6 and TNFalpha); and (4) cortisol. Previous research in HIV on each of these measures will be
reviewed in turn.

I.

CD4 T cells and Viral Load: Studies have extensively documented the

development o f clinical symptoms and AIDS conditions following rapid declines in CD4
T cells (Detels et al., 1987; Fahey et al., 1990). Although decline in CD4 T cell counts
has served as the hallmark for disease progression (Fahey et al., 1998; Pantaleo et al.,
1993; Staszewski, DeMasi, Hill, & Dawson, 1998), relatively weaker associations have
been reported between CD4 T cell counts and cognitive impairments in HIV/AIDS
(Bomstein et al., 1991; Dal Pan et al., 1998).
Increased levels of viral load in cerebrospinal fluid (CSF) and plasma have also
been correlated with the rate of CD4 T cell decline, poorer prognosis, and increased
clinical disease stages in HIV/AIDS (Hogervorst et al., 1995; Mellors et al., 1997). Some
studies have also reported a link between elevations in viral load and cognitive
impairment, especially for individuals diagnosed with AIDS dementia (Brew, Pemberton,
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Cunningham, & Law, 1997; Buffet et al., 1991; Farzadegan et al., 1992; Kim et al., 2001;
Royal, Seines, Concha, Nance-Sproson, & McArthur, 1994; Singer et al., 1994).
However, other studies have not found an association between plasma viral load and
cognitive decline in HIV infection (Dal Pan et al., 1998; Robertson et al., 1998). Ellis et
al. (1997) suggested that higher CSF viral load may only reflect increased risk of
cognitive impairments when significant corresponding declines in CD4 T cell counts are
also evident. Childs et al. (1999) compared the predictive value of both plasma viral load
and CD4 T cell counts as markers of dementia and sensory neuropathy in a sample of
1604 men with HIV infection over a 10 year period. Individuals with high plasma viral
loads had an 8.5 fold greater risk of developing dementia and 2.3 fold greater risk of
developing sensory neuropathy. Similarly, lower CD4 T cell counts were associated with
a 3.5 fold greater risk for dementia and 1.4 fold greater risk for sensory neuropathy.

II.

Neopterin: Neopterin is a compound derived from guanosine triphosphate that

is released from macrophages following activation. High concentrations of neopterin are
associated with production of reactive oxygen species. Hence, neopterin can serve as a
marker of the level of macrophage activation and an estimate of the extent of oxidative
stress in the immune system (Hamerlinck, 1999; Murr, Widner, Wirleitner, & Fuchs,
2002).
Neopterin is markedly elevated upon initial infection with HIV. Levels of
neopterin tend to decline somewhat after seroconversion, though they remain elevated in
more than 75% o f individuals with HIV in asymptomatic stages and progressively
increase with advancing disease stages (Baier-Bitterlich, Wachter & Fuchs, 1996; Fahey
et al., 1990; Fuchs et a l, 1989). Metha et al. (1996) reported that CSF levels o f neopterin
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progressively increased with advanced disease stages based on a subsample o f 377
participants from the San Diego HIV Neurobehavioural Research Center study.
Decreases in serum neopterin levels have also been documented after initiation of
HAART regimens (Amirayan-Chevillard et al., 2000; Stylianou, Aukrust, Bendtzen,
Muller, & Froland, 2000; Zangerele et al., 2002).
Griffin et al. (1991) examined serum and CSF concentrations of neopterin in 121
individuals with HIV infection and 62 HIV-negative controls. Levels of neopterin were
higher in individuals with HIV infection than the controls, and especially elevated in
HIV-positive individuals with neurological diseases, such as HIV associated meningitis,
opportunistic infections, and inflammatory demyelinating polyneuropathologies. CSF and
serum neopterin levels have also been correlated with measures of increased blood brain
barrier permeability (albumin ratio) in HIV-infected individuals at different stages of
disease (Andersson, Hagberg, Fuchs, Svennerholm, & Gisslen, 2001).

Ill: IL-6 and TNF-alpha: Peripheral proinflammatory cytokines are involved in
the initiation o f localized and systemic immune responses, such as activation of liver cells
to synthesize proteins necessary for other immune responses or vasodilation of blood
vessels to increase their permeability for proteins and immune cells at the infection site
(Janeway & Travers, 1997). They also monitor and modulate biological processes within
the periphery by both directly and indirectly communicating with the CNS (for review
see Maier & Watkins, 1998). Proinflammatory cytokines directly produced in the brain
are thought to have pivotal roles in protecting neurons and mediating inflammation.
However, both prolonged elevations and deficient levels can be detrimental to CNS
functioning (Wang et al., 2002).
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Plasma levels o f proinflammatory cytokines (IL-1, IL-6, and TNF-alpha) are often
elevated in HIV disease, especially among patients with opportunistic infections (Valdez
& Lederman, 1997-1998). Peripheral blood mononuclear cells isolated from patients with
HIV have been shown to spontaneously release high levels of IL-1, TNF-alpha and IL-6,
and increased release was correlated with advanced stages of HIV-1 infection (Berman,
Zaldivar, Imfled, Kenney, & Sandborg, 1994; Honda et al., 1990; Roux-Lombard,
Modoux, Cruchaud, & Dayer, 1989; Wright, Jewett, Mitsuyasu, & Bonavida, 1988).
Although an in vivo study conducted by da Silva, Singer, Fong, and Ottaway (1999)
found no differences in TNF-alpha and IL-6 levels at baseline, greater increases in serum
TNF-alpha

and IL-6

levels were evident after experimental

challenge

with

lipopolysaccharide in individuals with HIV infection (n = 29) than in control subjects (n
= 15).
Higher TNF-alpha and soluble TNF receptor concentrations in plasma were
associated with increased disease progression, lower CD4 and CD8 T lymphocyte counts,
and higher HIV mRNA levels (Aukrust et al., 1994; Godfried et al., 1994; Kulinkovich et
al., 1992). Ryan et al. (2001) reported that higher levels of soluble TNF-alpha receptors
in serum were correlated with the presence o f cognitive impairment and brain atrophy on
MRI scans in a sample o f 28 individuals with HIV infection. Increased serum TNF-alpha
was also noted in a sample o f individuals with HIV encephalopathy as compared with
HIV positive individuals without neurological disease (Grimaldi et al., 1991), and in
samples of AIDS patients with dementia, vacuolar myeopathy, and sensory neuropathy as
compared with AIDS patients without neurological disease (Wesselingh, Glass,
McArthur, Griffm, & Griffin, 1994).
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Similar elevations in TNF-alpha have been observed in CSF fluid o f individuals
with HIV infection as compared with HIV negative controls (Grimaldi et al., 1991; Tyor
et al., 1992). However, these studies did not confirm the correlation between TNF-alpha
levels and the presence of CNS disease.
Although some studies have demonstrated a positive correlation for IL-6 and IL-1
with disease progression, the association was weaker than those demonstrated for TNFalpha (Lathey, Kanangat, & Rouse, 1994; Martinez-Maza, 1992). Wesselingh et al.
(1993) compared mRNA expression of various cytokines in the brains o f individuals
diagnosed with and without HIV-related dementia. TNF-alpha levels were higher and IL1 and IL-4 levels were lower in individuals with dementia, whereas no differences were
noted in levels of IL-6, leukemia inhibitory factor, TGF-beta, or IFN-gamma mRNA
expression.
Seilhean et al. (1997) examined the association between cognitive impairment and
the extent of astrocytosis and TNF-alpha expression in specific brain regions (mid-frontal
cortex, subcortical and deep white matter, and basal ganglia) in 12 individuals diagnosed
with AIDS (8 who were diagnosed with dementia). Both density o f TNF-alpha
expression and astrogliosis were positively correlated with severity of cognitive
impairment.

IV Cortisol: Alterations in the circadian rhythm cycle of adrenal hormonal levels,
both elevations and suppressions, have been described in HIV-infected individuals during
all disease stages (Christeff et al., 1988; Kumar, Kumar, Morgan, Szapocznik, &
Eisdorfer, 1993; Membrano et al., 1987; Villette et al., 1990), though in many individuals
these changes may be subtle, not exceeding clinically defined ranges (Merenich,
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McDermott, Asp, Harrison, & Kidd, 1990). In a two-year longitudinal study, Findling et
al. (1994) reported that relatively fewer patients showed overt cortisol abnormalities.
However, a significant proportion of their sample of 53 patients (about 32%) exhibited
elevations in plasma ACTH toward the end of their study, possibly reflecting the
progression o f subclinical adrenal dysfunction.
Relatively few studies have looked at the significance of HP A abnormalities on
disease status separate from its affect on immune functioning. Lortholary et al. (1996)
reported higher mean serum concentrations of cortisol in a sample of 23 men with AIDS
(CDC stage IV) compared with 28 men with HIV infection that were asymptomatic or
mildly symptomatic (CDC stage II and III). They also noted that CD4 T cell counts were
inversely correlated with cortisol levels. Low levels of dehydroepiandrosterone (DHEA),
a physiological antagonist of cortisol, have also been observed in individuals with HTV
(Clerici et al., 1997b; Grinspoon & Bilezikian, 1992; Schifitto et al., 2000) and associated
with advanced disease progression (Jacobsen et al., 1991; Mulder et al., 1992).

Summary
Individuals with HIV infection frequently report that the presence of somatic
symptoms (especially chronic fatigue), neurocognitive impairments, and/or psychiatric
difficulties adversely impacts their activities of daily living and quality of life. However,
the pathogenesis of these symptoms is still poorly understood. A recent surge of research
in psychoneuroimmunology has provided corroborative evidence for links between
immune/HPA processes, mental status, and disease progression in various medical and
psychiatric disorders. A high density of proinflammatory cytokine and cortisol receptors
within the hypothalamus, medial temporal region, and frontal-subcortical systems
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suggests that these neural structures may be particularly sensitive to both systemic and
localized fluctuations in these molecules. These brain regions are responsible for
modulating a wide variety of physiological states, collectively referred to as “illness
behaviour.” The physiological, neuropathological, and behavioural consequences arising
from dysregulation of the immune/HP A system resembles some of the changes that
accompany HIV. In vitro studies have yielded a better understanding of the contributions
of immune and endocrine mediators to the pathogenesis of neurological insult in
HIV/AIDS. However, the broader implications of these findings to the variability in
clinical manifestations remains unclear. Although there continues to be a paucity of
literature on the in vivo connections between specific mediators of biological processes
and disease symptoms in HIV/AIDS, preliminary results summarized above suggest that
elevated systemic concentrations of these molecules may be associated with disease
progression and global measures of neurological functioning. More research is needed to
determine the significance of alterations in immune and endocrine levels on specific
neurocognitive, somatic, and depressive symptoms.
Study Objective and Predictions
This study was designed to expand upon previous research by exploring the
associations between systemic indicators of immune and HP A activation, specific
domains of cognitive impairment (as measured by neuropsychological test performance),
fatigue, depression, and self-reported cognitive symptoms in adults with HIV/AIDS. The
following

main

predictions

are

exploratory

in

nature,

derived

from

the

psychoneuroimmunological framework and previous research in other immune-mediated
illnesses reviewed above:

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

46
(1) Elevated proinflammatory cytokines (TNF-alpha and IL-6) and higher immune
activation (neopterin) will be associated with:
(a) Poorer performance on all neuropsychological domains (attention/working
memory, learning efficiency, and psychomotor/processing speed)
(b) Higher levels o f self-reported cognitive complaints (especially within the
memory domain)
(c) Elevated depressive symptoms
(d) Increased fatigue
(2) Higher serum cortisol will be associated with:
(a) Poorer performance on measures of learning efficiency,
attention/working memory, but not psychomotor/processing speed

possibly

(b) Higher levels of self-reported cognitive complaints (especially within the
memory domain)
(c) Elevated depressive symptoms
(d) Increased fatigue
(3) Elevated proinflammatory cytokines (TNF-alpha and IL-6), immune activation
(neopterin), and cortisol levels will be associated with traditional biological indicators of
disease status (i.e., lower CD4 T counts, higher CD8 T counts, and higher viral load).
Moreover, this study provides an opportunity to replicate research findings on the
links between depression, fatigue, cognitive complaints, illness symptoms, and
neuropsychological performance in an independent sample. The following corollary
predictions were made based on recent research from the Neurobehavioural Research
Unit at St. Michael’s Hospital:
(4) The symptom measures (i.e., depression, fatigue, cognitive complaints, and Illness
symptoms) will be highly associated with each other.
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(5) Of the symptom measures, only cognitive complaints will be modestly associated
with neuropsychological performance. In particular, self-reported cognitive symptoms
will be modestly associated with the processing speed and working memory domains.
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CHAPTER II
Methodology

Participants
Forty adults with confirmed HIV infection and no past or current use of HAART
medications (i.e., HAART-naive) took part in this study1. Given that antiretroviral
medications are intended to alter viral and immune functioning, the HAART-naive
participants were selected to reduce the possibility that the variability in biological
measures may be confounded by medications or other infections accompanying disease
progression. This study was approved by Research Ethics Boards at both St. Michael’s
Hospital (SMH) and the University of Windsor. All participants provided written
informed consent prior to their involvement in the study. Recruitment was conducted
through the Neurobehavioural Research Program in HIV/AIDS at SMH in Toronto, ON
by contacting physicians and posting flyers at HIV specialty clinics within the region.
Interested individuals were screened to exclude those with pre-existing neurological
conditions (e.g., CNS opportunistic infection, seizure disorder, or head injury with loss of
consciousness exceeding 30 minutes), developmental problems (e.g., diagnoses of
learning disability or attention deficit disorder), lower than a Grade 6 reading level,
significant medical illness (e.g., recent heart attack, kidney disease, or liver failure),
history of psychotic disorder, current intravenous drug use or treatment for substance
abuse, or taking medication known to significantly alter adrenocortical function (e.g.,
prednisone, dexamethasone, fludrocortisone acetate, or cyclophosphamide). Nine

1 Fifty-five adults with confirmed HIV infection actually took part in this study. The HAART-naive participants are
discussed in this paper. Preliminary findings for the sample o f 15 individuals on a stable HAART regimen for at least 1
l/ 2 years (i.e., HAART-stable) can be found in Appendix A.
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individuals were later removed from the analyses because they met one or more of the
aforementioned exclusionary criteria.
Demographic data for the remaining sample ( N - 31) are summarized in Table 5.
The sample was comprised of 26 males (84%) and 5 females (16%). Participants were
predominantly Caucasian (77%) and the majority reported sexual contact (90%) as a
major risk factor for HIY infection. According to CDC disease stages classification
(CDC: Centers for Disease Control and Prevention, 1992), 18 were asymptomatic (58%:
CDC A l or A2), 9 were mildly symptomatic (29%: CDC B1 or B2), and 4 had AIDSdefining illnesses or a nadir CD4 count of less than 200 (13%: CDC A3, B3, or Cl-3).
The means and standard deviations for the biological indicators, symptom
measures, and neuropsychological deficit scores are presented in Table 6. As a group,
participants demonstrate mildly elevated symptom measures and mildly impaired
neuropsychological test performance. Serum TNF-alpha and IL-6 concentrations for all
individuals fell within the expected clinical reference ranges. Serum neopterin levels for
9 participants were above the clinical cut-off (i.e., > 10 nmol/L) and clinically elevated
semm cortisol levels were observed in 6 participants (i.e., > 375 nmol/L).
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Table 5

Demographics for HAART-naive sample (N =31)

Variables

Mean (Standard Deviation)

Age (years)

35.6 (7.9)

Education (years)

13.4 (2.6)

WRAT reading (SS)

101.9 (9.8)

Recent CD8 Count

911.0(287.0)

Recent CD4 Count

541.6 (322.0)

Lowest CD4 Count

429.4 (220.3)

Recent Viral Load Log

3.9 (1.0)
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Table 6

Means and standard deviations o f the biological indicators, symptom measures, and
neuropsychological deficit scores for the HAART-naive sample (N =31)

Mean (Standard Deviation)

Variables

1149.0(604.4)

TNF-alpha mRNA

96.2(41.6)

IL-6 mRNA
TNF-alpha Elisa

8.5 (1.8)

IL-6 Elisa

0.6 (0.6)

Neopterin Elisa

8.3 (4.8)

Cortisol Elisa

280.9(100.9)

BDI Cognitive-Affective1

9.6 (7.0)

Piper Fatigue Total1

4.3 (2.1)

PAOF Total1

39.5 (21.1)

PAOF Memory1

15.1 (8.2)

Illness Total1

25.0(10.7)

Total2

0.69 (0.6)

Processing Speed

'y

Working Memory/Attention

0.13 (0.3)
1.45 (1.3)

Learning2
I

0.48 (0.7)
-y

'j

Raw scores; Composite deficit ratings
Note. BDI = Beck Depression Inventory; PAOF = Patient Assessment
of Own Functioning Questionnaire

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

52

Procedure
The entire research protocol took between 2 and 2 Vz hours, with testing and the
blood draw completed on the same day. Participants were briefly interviewed to gather
demographic information and then asked to complete questionnaires about subjective
cognitive symptoms, depressive symptoms, physical symptoms, and fatigue. A battery of
neuropsychological tests was selected to assess three domains commonly affected in
individuals with HIV-associated cognitive impairment: (1) attention and working
memory; (2) psychomotor efficiency and processing speed; and (3) learning efficiency
and memory.
Participants were asked to abstain from drinking alcohol the evening before and to
avoid eating any food and drinking caffeinated or soda beverages at least 1 Vz hours
before their blood samples were drawn. Blood samples were scheduled to be collected
between 10 am and 5 pm (with 80% completed between 10 am and 1:30 pm) to avoid
confounding the results by the natural increase in cortisol production often observed
during the early morning. Blood was drawn by medical personnel in the HIV specialty
clinic at SMH, and then transported for analysis to laboratories at SMH and the
University of Toronto (U of T). Written permission was also obtained to access routine
laboratory results from their physicians.
Measures

Demographic background. A brief interview was used to gather information
about sex, age, gender, and highest level of education. Screening questions about current
and past medical conditions, psychiatric history, and drug use were asked to confirm that
each participant met the inclusionary criteria described above.
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Disease status. Based on both CD4 T cell counts and symptomatology, the Center
for Disease Control (CDC, 1992) provides a classification system for successive stages of
HIV infection. Category A refers to individuals without any medical symptoms
(asymptomatic)

or

minimally

symptomatic

(e.g.,

persistent

generalized

lymphadenopathy). Category B refers to symptomatic individuals with mild physical
symptoms or minor opportunistic infections (e.g., oral candidiasis or herpes zoster).
Category C refers to individuals who exhibit more serious infections or AIDS-defining
illnesses (e.g., Pneumocystis carinii pneumonia, Karposi sarcoma or lymphoma, or
wasting syndrome). Each of these categories is further divided into levels 1 through 3
based on nadir CD4 T cell counts: (1) > 500 cells/mm3; (2) 200 to 499 cells/mm3; and (3)
< 200 cells/mm3 (CDC, 1992). Individuals were classified according to CDC93 stages
based on documented routine blood work results requested from the participant’s
physician and the presence of HIV-related or AIDS-defining illnesses obtained through
self-report in the interview.

Subjective symptoms. The Patient’s Assessment of Own Functioning Inventory
(PAOF: Chelune et al., 1986) was used to assess subjective cognitive complaints. The
PAOF is a self-report instrument that was “designed to elicit patients’ self-perceptions
regarding the adequacy of their functioning in various everyday tasks and activities”
(Chelune et al., 1986, p. 96). The questionnaire can be further subdivided into memory
(10 items), language and communication (9 items), sensory-perceptual and motor skills
(5 items), and higher level cognitive and intellectual functions (primarily executive-type
skills; 9 items) domains. Participants are instructed to rate how often they experienced a
particular kind of difficulty on a 6-point scale (0= almost never; 1= very infrequently; 2=
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once in a while; 3= fairly often; 4= very often; and 5= almost always). Total PAOF
scores are calculated by adding the ratings on all 33 items, while domain scores are
calculated by summing the ratings on the items comprising each domain. Higher scores
indicate more self-reported cognitive symptoms.
The Beck Depression Inventory (BDI: Beck & Steer, 1993) was used to assess the
presence and severity of depressive symptoms. The 21 items on this self-report
questionnaire are graded on a scale from 0 to 3 to reflect increasing symptomatology.
Standard clinical cut-offs for severity of depression have been defined: “minimal” (BDI <
10), “mild” (BDI 10 to 16), “moderate” (BDI 17 to 29), and “severe” (BDI >29). Items
can be further subdivided to obtain cognitive-affective (sum of items 1 to 13) and
somatic-vegetative (sum of items 14 to 21) scores. Unless otherwise indicated, cognitiveaffective scores were used in the analyses to avoid confounding the findings with somatic
items that may reflect the effects of HIV infection rather than depression. Cognitiveaffective scores of 10 or less show minimal symptoms of depression (i.e., “not
depressed”), while scores greater than 10 are suggestive of “moderate” depression. Of
note, the findings were consistent whether total or cognitive-affective scores were used in
the analyses.
The degree of physical symptoms was obtained through a checklist of 20 non
specific items (e.g., fever, dizziness, trouble sleeping, nausea, diarrhea, headache, skin
rash, muscles aches/joint pain, weight loss, appetite reduction, and loss of sexual libido).
Participants are asked to rate each item on a 5-point scale, indicating whether they have
not experienced the symptom in the past month (0) or the degree to which the symptom
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has bothered them over the past month (l=not at all; 2=a little; 3=a lot; 4=terribly).
Higher scores reflect the presence and severity of more physical symptoms.

Fatigue was measured using the Piper Fatigue Scale-Revised (PFS-R: Piper et al.,
1998). This instrument was designed and validated using a large sample of patients with
cancer. The PFS-R consists of 22-items with each question rated along a 10-point scale.
The total score also on a 10-point scale is obtained by summing all the items and dividing
by 22. Factor analyses used in the development of the PFS-R suggest that the scale taps
four dimensions: behavioural/severity (impact on activities and intensity), affective
meaning (emotional attributions), sensory (energy attributions), and cognitive/mood
(impact on thinking and feelings). Higher scores indicate an increased severity of fatigue
and greater impact o f fatigue on every day functioning.

Attention and Working Memory. Digit Span and Spatial Span, subtests of the
Wechsler Memory Scale-Third Edition (Wechsler, 1997), were designed to assess
auditory and visuospatial span/working memory, respectively. For Digit Span, the
individual hears a series of progressively longer numbers and is required to repeat each
series of numbers verbatim. Then, other number series are presented where the individual
is required to provide the numbers in the reverse order. For Spatial Span, the individual is
shown a board containing 9 blue-coloured blocks in a randomly spaced layout. The
individual is required to copy the order of progressively longer sequences of blocks
touched by the examiner, first in the same forward sequence as the examiner and then in
the reverse sequence as the examiner.
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Psychomotor efficiency and Processing speed. In the Symbol Digit Modalities
Test (SDMT: Smith, 1982), individuals are presented with a key that contains the
numbers 1 to 9 paired with different symbols. The individual is required to fill in the
corresponding numbers below a series of randomly ordered symbols as quickly as
possible by using the pairings in the key. The Trail Making Test and Grooved Pegboard
Test (GPT: Reitan & Wolfson, 1993) are components of the Halstead-Reitan
Neuropsychological Battery. Trails Part A requires the individual to connect in order a
series of numbers (e.g., 1 to 2 to 3...) randomly distributed over the page. The more
complex Trails Part B requires the individual to alternate between connecting a number
then a letter in their corresponding order (e.g., 1 to A to 2 to B ...). The Grooved
Pegboard Test involves psychomotor speed and dexterity in order to fit pegs into spaces
of various angles on a board. Separate scores are obtained for both the individual’s
dominant and non-dominant hands.

Learning efficiency and Memory. Verbal learning and memory was assessed by a
word list task developed at the University of Southern California (Parker, Eaton,
Whipple, Heseltine, & Bridge, 1995). The individual is orally presented with a list of 15
semantically unrelated nouns at a rate of one word every 2 seconds, and required to recall
as many words as they can in any order. The individual is given three learning trials with
the words presented in different orders each time. After a 30-minute delay, they are also
asked to recall as many words from the list and then to provide yes/no responses as a
means to determine if they can recognize the words amongst distracters. A variety of
outcome measures can be obtained from the profile of responses: (1) total correct
responses; (2) number o f perseverations or intrusions; (3) recall consistency across the
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three trials; (4) subjective organization; (5) serial position effects; (6) delayed recall; and
(7) recognition hits/false positives.
The Ruff-Light Trail Learning Test (Ruff & Allen, 1999) was used to assess
nonverbal learning and memory. The individual is presented with a series of
interconnected circles, and instructed to draw a trail with their finger moving one circle at
a time from the start to the finish. At each step, the individual receives feedback (“right”
vs. “go back”) by the examiner in order to assist in learning the specified 15-step trail.
The first time through is random (guided by the feedback), though more steps in the trail
are expected to be learned with each successive attempt. Learning efficiency is measured
by examining the number of trials required to learn the trail (maximum 10) and the
number of step errors made on each trial. Recall of the trail is also assessed after a 60minute delay period.

Composite deficit ratings. Performance on the neuropsychological tests in each of
the four domains was summarized into a composite clinical deficit rating based on a
modified application o f Heaton’s Global Deficit Score (GDS). The validity of the GDS
has been demonstrated in adults with HIV infection and has been described as a better
measure than individual test scores, especially when investigating populations with
“spotty” or subtle cognitive impairments (Carey et al., in press; Heaton et al., 1995).
Individual T-scores on each of the tests were recoded according to the following 6-point
scale: 0 = 40+ (normal), 1 = 35 to 39 (mild), 2 = 30 to 34 (mild to moderate), 3 = 25 to 29
(moderate), 4 = 20 to 24 (moderate to severe), and 5 = less than 20 (severe). Composite
deficit ratings for each domain were calculated by summing the recoded score for all tests
comprising the domain and then dividing by the total number of tests. Attention/Working
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Memory was comprised of Digit Span and Spatial Span scores. Processing Speed
included Trails A, Trails B, GPT dominant, GPT non-dominant, and SDMT. Learning
was comprised of the total scores on trials 1 to 3 for the REMT and the total scores on
trials 2 to completion of the RULIT. A Total deficit score was calculated by averaging all
three o f the deficit domain scores. A cut-off o f 0.5 has been defined as the optimal
balance between sensitivity and specificity in classifying individuals as normal versus
impaired (Carey et al., in press). Higher deficit rating scores correspond with increased
neuropsychological impairment.
Biological assays. Blood samples were collected in sodium citrate yellow top (8.5
ml) and serum gel separator tiger top (2 x 7ml) vacutainer tubes by trained personnel at
the HIV Specialty Clinic at SMH. Due to the light-sensitive nature of neopterin, the
samples were immediately covered by foil and subsequently processed and stored in dark
containers. The samples were delivered, in Saf-t-pak approved containers according to
GCP guidelines, to the J. Alick Little Lipid Research Laboratory at SMH, Core
Laboratory at SMH, and S. Der Research Laboratory at the U of T.

I.

mRNA expression: Estimates of TNF-alpha and IL-6 mRNA expression were

obtained by real-time quantitative polymerase chain reactions (PCR) procedures
performed at the U of T lab. Peripheral blood mononuclear cells (PBMCs) were first
isolated from the blood samples using Ficoll-Hypaque gradient centrifugation. RNA was
extracted from lysed PBMCs and quantified using optical density 260/280 spectrometry
(Eppendorf BioPhotometer). The quality of the mRNA sample was tested for degradation
by polyacrylamide capillary gel electropheresis using Agilent Bioanalyzer 2100. PCR
reactions were performed in a 3 84-well plate format using the ABI Prism 7900HT
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Sequence Detection System. cDNA was prepared by reverse transcription using 2ug of
RNA according to standard procedures. Real-time PCR amplification was conducted
using 10 ng of the reverse transcribed cDNA. The primers used in the procedure were
designed within the U of T laboratory:
( 1 ) HsTNFa-317/383 - AGCTGCCTTGGCTCAGACAT / GCTACATGGGAACAGCCTATTGT

(2) HsIL6-59/134

- CACTGGGCACAGAACTTATGTTG / AAAATAATTAAAATAGTGTCCTAACGCTCAT

Quantification procedures were performed in triplicate for each sample. Results represent
the average estimated copies of mRNA for each participant.

II.

Serum protein concentrations: The blood samples were immediately separated

by centrifuge, and the plasma was aliquoted, coded, and stored at -70° until assayed.
Serum concentrations of IL-6, TNF-alpha, and neopterin were obtained by trained
laboratory technicians in the Lipid laboratory using commercial enzyme-linked
immunosorbant assays (ELISA) kits according to manufacturer guidelines (BioSource
International & IBL Hamburg). Serum cortisol concentrations were assessed by
commercial radioimmunoassays in the SMH Core Laboratory according to manufacturer
directions. The following normative reference ranges were provided: IL-6 (0.100 pg/ml
to 10.73 pg/ml), TNF-alpha (< 20 pg/ml), neopterin (< 10 nmol/L), and cortisol (80
nmol/L to 375 nmol/L).
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CHAPTER III
Results
All statistical analyses were conducted using SPSS® for windows version 10 with
statistical significance defined as p < .05. One-tailed analyses were used because o f the
directionality inherent in the hypotheses. Graphical and statistical diagnostics were used
to detect the presence o f univariate or multivariate outliers, significant deviations from
normality, nonlinearity or heteroscedasticity (Tabachnick & Fidell, 1996). One outlier
(i.e., score < 3 standard deviations) was removed from the TNF-alpha mRNA analyses
due to its unduly influence on the results. The neuropsychological deficit scores and some
of the biological assays (TNF-alpha mRNA, IL-6 Elisa, and neopterin) were positively
skewed with many individuals scores within the normal range (i.e., lower values).
Transformations were not used in the analyses because the application of common
transformations to these variables did not significantly alter the distribution and the
interpretation of transformed measures is often unclear. Instead, results of nonparametric
tests or distribution-free tests were compared to those on parametric tests. As similar
patterns of findings were seen, the nonparametric results will be summarized below for
continuity among analyses with any major deviations highlighted.
Performance on neuropsychological deficit indices
Most individuals performed within the mildly impaired to average ranges as
determined by total and domain-specific deficit ratings (see Table 7). The working
memory index had the most restricted range of performance, while learning efficiency
showed the most variability. This must be taken into account when examining the
meaning of subsequent analyses, whether parametric or non-parametric, as the findings
may be limited by skewness and restricted range of values (Howell, 1999). The
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intercorrelations between the neuropsychological deficit ratings are presented in Table 8.
All domain deficit ratings were correlated with each other (p < .05), with the exception of
the learning efficiency and working memory/attention deficit ratings.
Associations between symptom measures
Spearman correlations were calculated to examine the relations among the various
symptom measures (see Table 9). Consistent with other studies, higher depression scores
were moderately correlated with the endorsement of more illness symptoms (p < .01).
Elevated depression scores were also modestly related to increased fatigue and total
subjective cognitive symptoms (p < .05). Fatigue and self-report of cognitive symptoms
were strongly correlated (p < .001) and illness symptoms were moderately associated
with both fatigue and total cognitive complaints (p < .01).
Associations between the various biological indicators
Spearman correlations were calculated to explore the relations among the various
biological measures (see Table 10). As predicted, the measures of proinflammatory
cytokine Elisa assays (IL-6 and TNF-alpha) were positively correlated (p < .01).
However, the mRNA expression of the proinflammatory cytokines was not associated.
Contrary to expected, mRNA cytokine serum protein concentrations were not correlated
with the corresponding estimated cytokine mRNA expression. Higher immune activation
as estimated by elevated neopterin levels was associated with higher recent viral loads (p
< .01) and lower recent CD4 T cell counts (p < .05), but not correlated with elevations in
recent CD8 T cell counts (p — .16). Interestingly, higher serum cortisol levels were
associated with lower CD4 T ceil counts (p < .05).
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Table 7
Frequencies o f individuals within impairment ranges across total and domain-specific
neuropsychological deficit indices within the HAART-naive sample (N —31)

Total

Processing
Speed

Working
Memory

Learning
Efficiency

Level o f Impairment

n (%)

n (%)

n (%)

n (%)

Average
Mild
Mild to Moderate
Moderate
Moderate to Severe
Severe

15
11
5
0
0
0

(48)
(36)
(16)
(0)
(0)
(0)

22
6
2
1
0
0

(71)
(19)
(7)
(3)
(0)
(0)

26
5
0
0
0
0

(84)
(16)
(0)
(0)
(0)
(0)

7
11
5
4
3
1

(23)
(36)
(16)
(13)
(10)
(3)
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Table 8

Spearman correlations (rs) showing the association between the total and domainspecific neuropsychological deficit ratings within the HAART-naive sample (N - 31)

Total

Total
Processing Speed
Working Memory/Attention
Learning Efficiency

Processing Working
Speed
Memory

1.00
0.76***
0.55***
0.85***

1.00
0.51**
0.42**

1.00
0.20

Learning
Efficiency

1.00

**p < .01 (1-tailed), ***p < .001 (1-tailed)
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Table 9
Spearman correlations (r<) showing the association between various symptom measures
within the HAART-naive sample (N = 31)

Depression

BDI Cognitive-Affective
Piper Fatigue Total
PAOF Total
PAOF Memory
Illness symptoms

1.00
0.39*
0.34*
0.21
0.52**

Fatigue

1.00
0.73***
0.64***
0.53**

Cognitive
Total

1.00
0.87***
0.42**

Memory

Illness

1.00
0.30

*p < .05 (1-tailed), **p< .01 (1-tailed)
Note. BDI - Beck Depression Inventory; PAOF=Patient Assessment of Own Functioning
Questionnaire
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Table 10
Spearman correlations (r j showing the association o f the biological indicators within
the HAART-naive sample (N = 31)

TNF-alpha
mRNA

IL-6
mRNA

Recent CD8
Recent CD4
Recent Viral Load

0.08
-0.03
-0.16

0.20
0.18
0.05

IL-6 mRNA
TNF-alpha Elisa
IL-6 Elisa
Neopterin Elisa
Cortisol Elisa

0.24
0.03
-0.12
0.05
-0.31

1.00
0.23
-0.08
0.01
-0.29

TNF-alpha
Elisa

IL-6
Elisa

Neopterin
Elisa

Cortisol
Elisa

-0.17
0.18
-0.09

0.06
-0.04
-0.13

0.24
-0.41*
0.52**

0.14
-0.38*
0.29

1.00
0.46**
0.28
-0.18

-----

-----------

-------------

1.00
0.16
-0.03

1.00
0.16

*p < .05 (1-tailed), **p< .01 (1-tailed)
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Associations between symptom measures and neuropsychological performance
The Spearman correlation coefficients for neuropsychological deficit ratings
across various symptom measures are presented in Table 11. Similar to previous research,
depressive symptoms and illness symptoms were not associated with neuropsychological
performance. Aside from the working memory/attention deficit score, neuropsychological
deficit ratings were also not associated with fatigue and cognitive complaints. Lower
working memory/attention deficit scores were, however, modestly associated with higher
fatigue (p < .01) and self-reported cognitive symptoms (p < .05).
Associations between biological indicators and neuropsychological performance
In

order

to

examine

the

relation

between

biological

measures

and

neuropsychological functioning, Spearman correlation coefficients were calculated
between the neuropsychological deficit ratings, cytokine serum concentrations, cytokine
mRNA expression, serum neopterin, and serum cortisol levels. Contrary to the
hypothesis, no consistent pattern of associations was found between the biological
indicators and neuropsychological performance (refer to Table 12).
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Table 11
Spearman correlations (r j showing the association between various symptom measures
and neuropsychological deficit scores within the HAART-naive sample (N —31)

Depression

Total
Processing Speed
Working Memory/Attention
Learning Efficiency

-0.18
0.03
-0.04
-0.30

Fatigue

Cognitive
Total

Memory

Illness

-0.21
-0.25
-0.37*
-0.08

-0.19
-0.21
-0.44**
-0.01

-0.17
-0.21
-0.36*
0.00

-0.13
-0.01
-0.04
-0.20

*p < .05 (1-tailed), **/?< .01 (1-tailed)
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Table 12

Spearman correlations (rj showing the association o f the biological indicators and
measures o f depression, fatigue, illness symptoms, cognitive symptoms, and cognitive
deficit indices within the HAART-naive sample (N - 31)

TNF-alpha
mRNA

BDI Cog-Aff1
Piper Fatigue Total1
PAOF Total1
PAOF Memory1
Illness Total1

0.12
-0.13
0.00
0.02
-0.23

Total2
Processing Speed2
WM/Attn2
Learning2

0.18
0.18
-0.02
0.07

IL-6
mRNA

0.40*
0.38*
0.21
0.28
0.16
-0.04
-0.06
-0.06
0.01

TNF-alpha
Elisa

IL-6
Elisa

Neopterin
Elisa

Cortisol
Elisa

0.13
0.04
-0.12
-0.16
-0.19

0.18
0.13
-0.16
-0.35*
0.24

0.28
0.07
0.15
0.16
0.06

-0.04
-0.05
-0.19
-0.10
0.06

-0.12
-0.06
-0.32*
-0.14

0.00
0.08
-0.11
-0.10

0.11
0.02
-0.17
0.20

-0.23
-0.23
-0.06
-0.12

1Raw scores; 2Composite
• deficit
• ratings
*p < .05 (1-tailed), **p< .01 (1-tailed)
Note. BDI Cog-Aff = Beck Depression Inventory Cognitive-Affective score; PAOF =
Patient Assessment o f Own Functioning Questionnaire; WM/Attn = Working Memory
and Attention
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Associations between biological indicators and symptom measures
Spearman correlations between the six biological measures, depressive symptoms
(BDI cognitive-affective), fatigue (PFS-R total scores), subjective cognitive symptoms
(PAOF total and memory scores), and total illness symptoms (HIV symptom checklist)
are summarized in Table 12. As predicted from the literature, higher depressive
symptoms were modestly associated with elevated IL-6 mRNA expression (p < .05).
Modest positive correlations were also noted for IL-6 mRNA expression and fatigue (p <
.05). A similar pattern of findings was obtained with the Pearson product-moment
correlations, though the associations between the biological indicators and symptom
measures were stronger. This may partly reflect the fact that nonparametric tests have
lower power relative to the corresponding parametric test (Howell, 1999). The Pearson
correlational analyses showed that IL-6 mRNA expression was correlated with all
symptom measures, including depression (r = 0.50, p < .01), fatigue (r = 0.33, p < .05),
total cognitive complaints (r = 0.32, p < .05), memory complaints (r - 0.31,p < .05), and
illness symptoms (r = 0.34, p < .05). Higher serum neopterin was also associated with
elevated depressive symptoms (r = 0.33,p < .05).
Given the high intercorrelations between symptom measures, partial correlations
were used to further tease apart the relations with IL-6 mRNA expression. When the
influence of depression was controlled, IL-6 mRNA expression was no longer correlated
with fatigue (pr = 0.19, p = .174), illness symptoms (pr = 0A0, p = .31), total cognitive
complaints (pr - 0.18,/? - .19), or memory complaints (pr = 0.21, p - .08). Inversely, the
association between depression and IL-6 mRNA expression weakened but remained
statistically significant after removing the influences of fatigue, total cognitive
complaints, and illness symptoms (pr = 0.39, p < .05).
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A s s o c ia tio n s b e tw e e n

severity o f depression a n d IL-6 mRNA and neopterin levels

Individuals were grouped according to the severity of their depression in order to
clarify the relation between depressive symptoms, IL-6 mRNA expression, and serum
neopterin levels. In order to capture the range of severity, groups were

d e fin e d

according

to standard clinical cut-offs on the total BDI score (Beck & Steer, 1993): “minimal” (BDI
< 10), “mild” (BDI 10 to 16), “moderate” (BDI 17 to 29), and “severe” (BDI >29).
Participants’ concentrations of IL-6 mRNA
of depression

a re

and

neopterin divided across the four levels

shown in Figures 3 and 4. Although the small number of individuals in

each group limits the generalizability of these findings, some interesting patterns can be
seen. All o f the severely depressed individuals showed high IL-6 mRNA expression (i.e.,
above 125 copies/lOng of c-DNA) and high neopterin levels (i.e., close to or above the
clinical cut-off of 10 nmol/L).
One-way ANOVAs verified that differences existed between depression severity
subgroups for both IL-6 mRNA expression [F(3, 24) - 7.72, p < .001] and serum
neopterin concentrations [F(3, 26) = 3.39, p < .05]. Pairwise multiple comparisons were
completed to specifically determine which of the groups’ means differed from each other.
The Bonferroni method, which assumes equal variances (supported by non-significant
Levene statistics), was selected to adjust for inflation of Type I error rate with multiple
comparisons. The severely depressed individuals had higher mean IL-6 mRNA
expression compared with the means for the moderate (p < .01), mild (p < .01), and
minimally (p < .001) depressed groups (see Figure 5). The severely depressed individuals
had higher mean serum neopterin levels compared with the means for mild (p < .05) and
m in im a lly

(p <.05) depressed groups, but

w as

not different

fro m

the mean of the

moderately depressed group (see Figure 6).
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Figure 3. Scatterplot showing IL-6 mRNA expression for individual participants divided
according to the severity of their depressive symptoms.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

72

25.00-”

3

20.00-

o
£
S'm 15 . 00 w
LU
C

10-00-j

a
s
Z

5 .0 0 -

Minimal

Mild

M o d erate

S ev ere

Severity of D ep ressio n
Figure 4. Scatterplot showing serum neopterin concentrations for individual participants
divided according to the severity of their depressive symptoms.
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Figure 5. Mean IL-6 mRNA expression as a function of depression severity.
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Figure 6. Mean serum neopterin concentrations as a function of depression severity.
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Potential confounding influences on the biological measures
Interactions with antidepressant medications. The influence of antidepressants
on the association between IL-6 mRNA expression, serum neopterin, and depression was
explored by grouping participants into those currently using antidepressants (n - 18) and
those not taking any antidepressants (n = 13). All types of antidepressants (e.g., tricyclics
and selective serotonin reuptake inhibitors) were considered together given the small
sample size. Means and standard deviations for age, education, estimated reading level,
blood indicators, biological measures, and symptom measures for the separate
antidepressant groups are provided in Table 13. No differences were evident between the
individuals taking and not taking antidepressants on the demographic variables, with the
exception of the mean age for the antidepressant group being slightly higher than the
mean age of those not taking any antidepressants [F (1, 29) = 4.33, p < .05]. Mean
biological indicators and symptom measures were not different for participants taking
versus not taking antidepressants.
Given the reduced power associated with nonparametric tests and the small
sample sizes, both Pearson (r) and Spearman (rs) correlations between depressive
symptoms (BDI cognitive-affective scores), IL-6 mRNA expression, and serum neopterin

levels are separately calculated for the antidepressant groups. Depressive symptoms and
IL-6 mRNA expression remained modestly associated for both the antidepressant (rs =
0.32,p = .14; r = 0.60, p < .05) and no antidepressant groups (rs - 0.45, p < .05; r = 0.39,

p = .08). On the other hand, an interesting interaction was observed for neopterin serum
concentrations and depressive symptoms across antidepressant groups. Although
neopterin and depressive symptoms were strongly associated in the antidepressant group
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(rs = 0.83, p < .001; r = 0.78, p < .001), the association was nullified in the group not
taking any antidepressants (rs = -0.25, p > .05; r — -0.08, p > .05). These findings are
graphically illustrated by the scatterplot in Figure 7.
In order to further investigate the nature of this interaction, individuals were
divided into not depressed and depressed groups based on a BDI cognitive-affective cut
off score o f 10 (Beck & Steer, 1993). Participants’ concentrations o f IL-6 mRNA and
neopterin for depressed versus non-depressed individuals are separately shown by
antidepressant groups in Figures 8 and 9. Despite the small number o f individuals in each
group, some interesting patterns are evident. For individuals taking antidepressants,
variability in IL-6 mRNA expression was apparent for both depressed and not depressed
individuals. Although variability was also apparent among individuals not taking
antidepressants, a greater proportion of depressed as compared with non-depressed
individuals had higher levels of IL-6 mRNA expression. Depressed individuals taking
antidepressants showed relatively higher neopterin serum concentrations in comparison
with non-depressed individuals taking antidepressants. In fact, all six depressed
individuals on antidepressants were above the clinical reference range for neopterin (i.e.,
cut-off >10 nmol/L) while all seven non-depressed individuals on antidepressants were
within normal expectations. More variability was seen among both the depressed and
non-depressed individuals not on antidepressants, though the majority (80%) of
individuals not taking antidepressants had serum neopterin levels within normal limits.
ANOYAs separately performed by antidepressant group provided further support
for an interaction between depression, antidepressants, and neopterin levels. Although
mean neopterin levels of the depressed and non-depressed groups were not different for
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those not taking antidepressants [F(l, 15) = 0.00, p > .05], mean neopterin levels were
higher in the depressed as compared to non-depressed group for those taking
antidepressants [F(l, 11) = 45.66,p < .001] (see Figure 10).
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Table 13

Demographic data, biological indicators, and symptom measures for HAART-naive
individuals on (n = 13) and not on antidepressants (n ~ 18)

Mean (Standard Deviation)

Antidepressants
(n= 13)

No Antidepressants
(n= 18)

Age (years)*

38.8 (9.0)

33.2 (6.3)

Education (years)

13.3 (2.6)

13.5 (2.6)

WRAT reading (SS)

101.9 (9.6)

101.9 (10.3)

Recent CD 8 Count

941.4 (331.0)

873.8 (236.3)

Recent CD4 Count

593.5 (360.5)

499.4 (292.2)

Lowest CD4 Count

453.6 (248.2)

412.4 (204.5)

4.0 (0.9)

3.7 (1.0)

TNF-alpha mRNA

961.8 (373.3)

1298.7(717.5)

IL-6 mRNA

103.7 (48.8)

89.7 (34.7)

TNF-alpha Elisa

8.8 (1.0)

8.2 (2.2)

IL-6 Elisa

0.7 (0.5)

0.6 (0.8)

Neopterin Elisa

8.8 (4.6)

7.9 (5.0)

265.8 (87.8)

292.5(111.1)

BDI Cognitive-Affective

9.2 (8.2)

9.9 (6.1)

Piper Fatigue Total

4.6 (1.1)

4.0 (2.7)

PAOF Total

39.9 (18.7)

39.2 (23.3)

PAOF Memory

15.0(8.0)

15.1 (8.7)

Illness Total

23.2 (9.8)

26.4 (11.4)

Variables

Recent Viral Load Log

Cortisol Elisa

* p < .05 (Means differ for two groups)
Note. BDI- Beck Depression Inventory; PAOF = Patient Assessment o f Own
Functioning Questionnaire
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Figure 7. Scatterplot showing the relations between depressive symptoms and serum
neopterin levels separated by antidepressant groups.
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Figure 8. Scatterplots showing the relations between depressive symptoms and IL-6
mRNA expression separated by antidepressant groups.

Note. No = individuals not taking any antidepressant medication, Yes = individuals
taking antidepressants
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Figure 10. Mean serum neopterin concentrations for depressed and non-depressed
individuals separated by antidepressant groups.

Note. No = individuals not taking any antidepressant medication, Yes = individuals
taking antidepressants
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Sex. Differences in production and cyclic regulation o f hormones between the
sexes could potentially influence the biological measures. In particular, cortisol levels can
be suppressed by the presence of other hormones which considerably vary over the
month in females. Although there are too few female participants to analyse sex as
separate groups, the association between biological assays and symptom measures was
examined with the 5 female participants removed from the sample. Taking into
consideration the reduction in power due to fewer participants overall, the pattern of
results essentially remains unchanged. IL-6 mRNA expression was correlated with all the
symptom measures: BDI cognitive-affective (rs —0.54, p < .01; r —0.57, p < .01), Piper
Fatigue Scale (rs = 0.51, p < .01; r = 0.44, p < .05), PAOF total (rs — 0.38, p < .05; r =
0.39, p < .05), PAOF memory (rs = 0.43, p < .05, r = 0.42, p < .05), and to a lesser extent
with HIV symptom checklist {rs - 0.29, p = .09; r - 0.43, p < .05). A more modest
association was present between serum neopterin levels and depressive symptoms (rs ~
0.26, p = .1; r = 0.37, p < .05), though neopterin and depressive symptoms remained
strongly correlated in the group of individuals taking antidepressants (rs - 0.80, p < .001;
r = 0.75, p < .01). The correlation coefficients for the other biological indicators
(including serum cortisol) with symptom measures and neuropsychological deficit ratings
were non-significant.
Disease stage. Severity of

d is e a s e

progression could also potentially impact the

biological measures. Although the majority of individuals in the HAART-naive group
were asymptomatic (n - 18, 58%) or mildly symptomatic in = 9, 29%) as defined by
CDC93 staging criteria, 4 individuals had AIDS-defining illnesses or a nadir CD4 count
of less than 200. The correlational analyses were rerun without the four individuals at

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

advanced stages. IL-6 mRNA expression remained associated with scores on the BDI
cognitive-affective (rs = 0.45, p < .01; r = 0.53, p < .01) and to a lesser degree with the
Piper Fatigue Scale (r, = 0.40, p < .05; r - 0.39, p < .05), PAOF total (rs = 0.24, p = .13; r
= 0.34,/? = .05), PAOF memory (rs = 0.28,/? = .09; r = 0.37,/? < .05), and HIV symptom
checklist (r5 = .19,/? = .18; r = 0.36,/? < .05). In contrast, the association between serum
neopterin and BDI cognitive-affective scores was weakened and no longer statistically
significant (rs = 0.20, p = .16; r = 0.27, p = .09) when the participants with AIDS were
removed. This may stem, in part, from the reduced sample size, decreased variability in
neopterin values, as well as the influence of the AIDS individuals, as three out of the four
participants with AIDS had elevated serum neopterin levels outside the normal reference
range (see Figure 11). However, the association between neopterin and depressive
symptoms remained strongly correlated in the group of individuals taking antidepressants

(rs - 0.88,/? < .001; r = 0.84,/? < .001).
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Figure 11. Scatterplot showing serum neopterin levels across disease stage.
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CHAPTER IV
Discussion
Traditionally, neuropsychology has been concerned with explaining human
behaviour in terms o f central nervous system (CNS) functioning (i.e., defining brainbehaviour relationships). Recent work in the field of psychoneuroimmunology provides
mounting support for integral connections between systemic biological processes
(immune and endocrine) and key brain systems responsible for governing a wide variety
of physiological and behavioural responses including affect and cognition. Transient
elevations in biological mediators (cytokines and hormones) are pivotal for instigating
physiological responses that permit adaptation to environmental changes including
physical (e.g., acute infection) and psychological stressors (e.g., perceived threats).
“Illness or sickness behaviours” consequently arise as the body redistributes resources
and actively fights acute infections: fever, malaise, fatigue, depressed mood, decreased
appetite, accelerated weight loss, increased need for sleep, reduced sex drive, increased
sensitivity to pain, and reduced cognitive efficiency. While adaptive in the short-term,
chronic dysregulation o f biological processes and associated prolongation of “illness
behaviours” could significantly impede an individual’s ability to function in everyday
life.
“Illness behaviours” resemble the somatic, affective, and cognitive symptoms
often accompanying various medical conditions, including those frequently present in
individuals with HIV/AIDS. As a result of remarkable advancements in antiretroviral
drug therapies over the past 20 years, many individuals are now living and coping with
HIV as a chronic illness. Although medications have effectively slowed disease
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progression, symptoms of chronic fatigue, depression, and cognitive difficulties remain
prevalent and often adversely impact quality of life. Management of these clinical
symptoms can be challenging given the complexity of potential factors (both biological
and psychological) that may underlie the differential expression across individuals. While
immune and endocrine dysfunction in HIV has been well-described at a cellular
pathophysiological level, there remains a paucity of literature examining the possible
links between these biological alterations and the development of specific clinical
symptoms.
This pilot study aimed to integrate biological studies on the neuropathogenesis of
HIV within a broader clinical context by exploring the associations of systemic indicators
of immune system (neopterin, IL-6, and TNF-alpha) and HPA axis (cortisol) activation
with the presence and severity of the following clinical symptoms in a sample of 31
HAART-naive participants with HIV infection: (1) specific domains of cognitive
impairments as measured by performance on neuropsychological tests (attention/working
memory, learning efficiency, and psychomotor/processing speed); (2) self-reported
cognitive symptoms; (3) a subjective measure of fatigue; and (4) self-reported depressive
symptoms.

Evaluation o f Predictions and Study Limitations
Hypothesis 1. The first prediction was only partially supported in this pilot
investigation. While immune markers were not correlated with objective measures of
cognitive impairment in the present study (Hypothesis la), associations were obtained
between some immune markers and subjective symptom measures (Hypotheses lb to d).
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I.

Symptom measures: Elevated immune activation (as measured by serum

neopterin levels and mRNA expression of the proinflammatory cytokine IL-6) was
associated with depressive symptoms. Higher serum IL-6 mRNA expression was also
modestly associated with elevated fatigue, total and memory cognitive complaints, and
illness symptoms, though only the relation with depression remained significant after the
overlapping influences of the other symptom measures were removed. More specifically,
both the presence and severity of depressive symptoms were related to elevated immune
activation, such that the most severely depressed individuals in this sample showed
higher levels o f IL-6 mRNA expression and neopterin concentrations. Similarly, several
recent investigations have shown links between depression and immune activation, as
measured by both elevated serum IL-6 and neopterin in depressed individuals (e.g.,
Bonaccorso et al., 1998; Musselman et al., 2001; Schlatter et al., 2004; Trzonkowski et
al., 2004; Zautra et al., 2004). In general, studies comparing patients diagnosed with
Major Depressive Disorder (with or without comorbid medical conditions) versus nondepressed individuals have found group differences in mean levels of serum immune
measures, whereas relatively fewer studies have found an association between biological
measures and the severity of depression (see Table 3). While condition/control group
differences are initially useful in identifying measures of interest to study, they provide
limited information about the individual variability in symptom expression within a
medical condition. More in-depth exploration of factors within a specific condition is
necessary for identifying subgroups and associated characteristics that may place
particular individuals at higher risk for the development of certain clinical symptoms.
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In the present study, the effects of antidepressant medication on the link between
immune activation and depressive symptoms was explored. Although no association was
evident in the individuals not taking antidepressants, neopterin and depressive symptoms
were strongly associated in the group of individuals currently taking antidepressants. In
the antidepressant group, some of the individuals showed both reduced depressive
symptoms and lower neopterin levels, suggesting that the antidepressant medications
were effective. In contrast, a subsample of individuals on antidepressants continued to
endorse high levels of depressive symptoms and had elevated neopterin levels. This
subsample may represent individuals not responding to the treatment similar to
previously described treatment-resistant groups (Kubera et al., 2004; Lanquillon et al.,
2000). Both Xia et al. (1996) and Maes et al. (1999) have demonstrated
immunosuppressive effects of antidepressants in vitro using serum from healthy adults. In
contrast, most in vivo studies have failed to show significant changes in immune markers
with short-term (< 3 months) antidepressant treatment in inpatient or acutely depressed
samples (see Table 4). Many individuals require long-term treatment with antidepressants
to achieve desired prolonged effects. Although data on the duration of antidepressant
treatment was not systematically collected in the present study, the available information
suggests that many individuals in the present sample had been taking the antidepressants
much longer than 3 months. Moreover, mean c h a n g e scores used in previous
investigations may obscure individual differences in biological markers, whereas the
consideration of each individuals’ post-treatment levels relative to standard clinical cut
offs in the present study permitted the isolation of subsamples within the antidepressant
group (see Figure 9). Similarly, when Lanquillon et al. (2000) examined treatment
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responders and non-responders separately, a decline in some immune markers was
apparent but only for the individuals who were responding to the antidepressant at 6
weeks.
II.

Cognitive

im p a irm en t.

Contrary to expected, no consistent pattern o f

association was found between the biological indicators and neuropsychological
performance across total, attention/working memory, learning efficiency and memory,
and psychomotor/processing speed deficit ratings in the present sample. Several potential
explanations may be offered for the absence of this association. Although the HIV virus
has been shown to enter the CNS within days to weeks of infection (e.g. Davis et al.,
1993; Resnick et al., 1988), cognitive impairments are rarely evident at diagnosis and
increase in prevalence with duration of the illness and advancing disease stage (Bomstein
et al., 1993; White et al., 1995). Research on the cellular mechanisms underlying
neurotoxicity suggest that the HIV virus does not directly infect neurons but instead is
stored and transported to the brain via macrophages. The release of viral and cellular
toxins (e.g., proinflammatory cytokines or oxygen radicals) from chronic low-grade
activation of macrophages is thought to indirectly damage the CNS (e.g., Gendelman et
al., 1994; Minagar et al., 2002). Given the complexity and resilience of the brain,
multiple insults exacerbated by transient states of heightened immune activation (that
also perpetuate phases of more intense viral replication) may be required prior to showing
significant cognitive impairments as measured by below expected performance on
neuropsychological tests. As such, measurement of an individual’s biological status at a
single time-frame may not accurately correlate with the damage already done to the CNS.
While transient fluctuations in proinflammatory cytokines and immune activation may
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contribute to the mild, intermittent cognitive inefficiency experienced in every day life, a
single session of objective neuropsychological tests may not capture these subtle
subjective cognitive changes as individuals may be able to compensate within the testing
session. Neuropsychological testing provides an estimate of the individual’s best
cognitive performance within an isolated and time-limited context. However, this
performance may be unrepresentative of the ongoing demands faced in everyday
situations especially in individuals with relatively mild changes in their cognitive
abilities. On the other hand, more stable or chronic elevations in biological indicators of
immune activation may accompany further deterioration of immune system functioning
at advanced disease stages (e.g., Aukrust et al., 1994; Baier-Bitterlich et al., 1996;
Kulinkovich et al., 1992). This may account for why a few studies have found
associations between elevated immune activation (in particular neopterin and TNF-alpha)
and more frank neurological impairment or dementia (Ryan et al., 2002; Seilhean et al.,
1997), HIV encephalopathy (Grimaldi et al., 1991), as well as the presence of
neurological diseases,

such as meningitis,

CNS

opportunistic

infections, and

inflammatory demyelinating polyneuropathies (Griffin et al., 1991; Wesselingh et al.,
1994) in patients diagnosed with AIDS.
Another possibility could be that a more modest association was obscured due to
the size and characteristics of the present sample. While the sample size is adequate to
detect a moderate or strong correlation, a much larger sample size (N > 150) may be
needed to detect a more modest association (Howell, 1999). Although some preliminary
studies (e.g., Kirschbaum et al., 1996; Kozora et al., 2001; Reichenberg et al., 2001;
Spath-Schwalbe et al., 1998) with similar sample sizes have obtained modest correlations
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between biological indicators and cognitive impairments in other medical conditions or in
healthy individuals under experimental manipulations (see Table 2), larger samples of
adults with HIV infection may be needed given the demographic and clinical variability
in this population. For example, other studies have required large sample sizes in order to
capture small but clinically significant relations between neuropsychological performance
and subjective cognitive complaints in samples of adults with HIV infection (e.g., Carter
et al., 2003; Rourke et al., 1999a).
In addition to suppressing viral replication, initiation of antiretroviral medications
may be accompanied by reductions in biological indicators of immune activation such as
neopterin (e.g., Amirayan-Chevillard et al., 2000; Zangerele et al., 2002). Opportunistic
infections, more frequently present with advanced disease progression, may alter immune
status and cytokine profiles (e.g., Valdez et al., 1997-1998). HAART-naive participants
were specifically selected to reduce these potential confounds. Physicians typically
initiate HAART treatment when CD4 T cell counts significantly drop (often below 200)
and symptoms ensue. Hence, the majority of the HAART-naive sample were
asymptomatic (58%) and mildly symptomatic (21%) according to CDC disease stage
classification criteria (CDC, 1992). Hence, the manifestation of clinical symptoms in the
present sample may have been reduced by this selection bias. The restricted variability in
neuropsychological test performance and biological measures (i.e., most scores within
normal limits) may have contributed to the limited findings.

Hypothesis 2. Higher serum cortisol was not associated with poorer performance
on the neuropsychological measures, higher self-reported cognitive complaints, elevated
depressive symptoms, nor increased fatigue in the present sample. These findings are
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contrary to previous studies (cited in Tables 1, 2, and 3) showing associations between
elevated cortisol and higher fatigue, depressive symptoms, and impaired cognitive
function. The link between elevated cortisol and impaired cognitive function (in
particular on measures o f verbal declarative memory) has been consistently demonstrated
using experimental manipulations (corticosteroid administration or exposure to
psychosocial stressor) in healthy participants (e.g., Kirschbaum et al., 1996; Newcomer et
al., 1999). Higher cortisol levels have also been associated with cognitive impairment,
depression, or fatigue in medical conditions that have significant alterations in adrenal
functioning due to the disease process itself (e.g., Cushing’s syndrome, early withdrawal
of alcoholics, or Alzheimer’s disease), treatment with corticosteroids (e.g., rheumatoid
arthritis), or under conditions of dexamethasone suppression (e.g., Major Depressive
Disorder) (e.g., Errico et al., 2002; Keenan et al., 1995; Mauri et al., 1993; Starkman et
al., 1992; Van Loden et al., 1998; Umegaki et al., 2000; Weiner et al., 1997; Wolkowitz
et al., 1990). While alterations in the circadian rhythm cycle o f adrenal hormonal levels
have been documented in some individuals with HIV infection (e.g., Christeff et al.,
1988; Kumar et al., 1993; Villette et al., 1990), most studies have failed to find overt
HP A abnormalities in the vast majority of individuals with HIV especially in individuals
at early disease stages (e.g., Findling et al., 1994; Merenich et al., 1990). The association
between higher serum cortisol levels and advanced disease progression (Findling et al.,
1994; Lortholary et al., 1996) may reflect dysregulation from mounting stressors and/or
direct pathological consequences of the HIV virus or opportunistic infections on the
endocrine/immune negative regulatory mechanism (refer to Figure 2). In the present
sample, the estimated serum cortisol levels taken at a single tlme-point in the late
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morning to early afternoon fell within normal limits for most individuals (81%).
Inclusion of more participants at advanced disease stages may increase the variability of
cortisol levels within the sample. The potential subclinical dysregulation of the HPA axis
in HIV infection may be better captured by measuring cortisol over the entire 24 hour
cycle, as alterations may be more apparent at peak times early in the morning or trough
times in the late evening. Given the broadly defined normal range of cortisol levels,
measurement of disproportionate responses following experimental manipulations of the
HPA axis (e.g., dexamethasone suppression, challenge with lipopolysaccharide, or
presentation with psychological stressors) may provide a more effective means to
examine individual alterations and their association with clinical symptoms in individuals
with HTV infection.

Hypothesis 3. Contrary to previous investigations (e.g., Aukrust et al., 1994;
Godfried et al., 1994; Kulinkovich et al., 1992), the serum and mRNA expression of
proinflammatory cytokines were not directly associated with traditional biological
indicators of disease status (i.e., lower CD4 T counts, higher CD8 T counts, and higher
viral load). Given the possibility of more transient alterations in proinflammatory
cytokine levels at early disease stages, single measures of biological indicators may be
insufficient for tracking

corresponding

changes

in

immune

functioning.

The

inflammatory cytokine cascades observed in typical immune responses to infection
(Janeway & Travers, 1997) suggests that increased cytokine production may not directly
accompany but, in fact, precede resultant immune cell alterations (e.g., cytokines trigger
macrophage and CD4 T cell recruitment and stimulation, which may, in turn, enhance
viral infection of immune cells and subsequent viral replication). Associations apparent in
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studies of individuals across disease stages may reflect the chronic elevations in
proinflammatory cytokines with more advanced disease progression (Aukrust et al.,
1994; Godfried et al., 1994; Kulinkovich et al., 1992). Longitudinal studies sampling
biological indicators across multiple time points may provide a means to further elucidate
the exact nature of the relation between proinflammatory cytokines and disease
progression in HIV.
On the other hand, reservoirs of the HIV virus contained within macrophages are
thought to instigate the chronic low-grade activation and release of toxins from the host
macrophage (Gendelman et al., 1994; Minagar et al., 2002). Hence serum neopterin
levels, a general marker of macrophage activation and the extent of oxidative stress
within the immune system, may be more directly correlated with recent measures of
immune cell functioning (CD4 and CD8 cells) and viral replication (viral load). In the
present study, elevated serum neopterin levels were associated with some of the
traditional markers o f disease progression (i.e., higher recent viral loads and lower recent
CD4 T cell counts, but not correlated with elevations in recent CD8 T cell counts). This
finding is consistent with a few previous investigations documenting elevated neopterin
levels in many individuals at early disease stages and showing subsequent increases in
neopterin levels with advanced disease status (e.g., Baier-Bitterlich et al., 1996; Fahey et
al., 1990; Metha et al., 1996).
Interestingly, higher serum cortisol levels were also associated with lower CD4 T
cell counts in the present sample. Lortholary and colleagues (1996) reported a similar
finding in a study comparing cortisol levels in individuals across disease stages. Elevated
cortisol levels may hasten progression of HIV infection by altering cellular metabolism
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(Brooke and Sapolsky, 2000) or by suppressing cell-mediated immunity and the
production o f Type 1 cytokines such as IL-2, IL-12, and IFN-gamma (Clerici et al., 1997;
Rook et al., 1993; Sapse, 1997). A shift toward humoral immunity and elevated type 2
cytokines (IL-4 and IL-10) may trigger destruction of CD4 T cells, reduce the efficacy of
cytotoxic mechanisms at eliminating HIV-infected cells, and/or initiate a less effective
means (i.e., antibody neutralization) to manage the HIV virus. This imbalance in type 1
and type 2 expression has frequently been described in individuals with HIV infection
especially at advanced disease stages (Clerici et al., 1997b; Fauci, 1996; Klein et al.,
1997; Salvaggio, Balotta, Galli, & Clerici, 1995) and has been associated with reduction
in CD4 T cell counts, time to AIDS diagnosis, and time to death (Dolan et al., 1995;
Luceyetal., 1991).

Hypotheses 4 and 5. This study also provided an opportunity to replicate research
findings on the links between depression, fatigue, cognitive complaints, illness
symptoms, and neuropsychological performance in an independent sample. Consistent
with other studies, elevated depression scores were associated with increased fatigue
(Millikin et al., 2003), endorsement of more illness symptoms (Carter et al., 2003), and
higher subjective cognitive symptoms (e.g., Bassel et al. 2002; Beason-Hazen et al,
1994; Hinkin et al., 1996; Moore et al., 1997; Rourke et al., 1999a). Total subjective
cognitive complaints were also associated with fatigue (Millikin et al., 2003) and illness
symptoms (Carter et al., 2003). While symptom measures were expected to be highly
intercorrelated, neuropsychological performance was not expected to be associated with
subjective symptoms of depression, fatigue, or medical illnesses based on previous null
findings in large samples of individuals with HIV/AIDS (e.g., Carter et al., 2003; Millikin
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et al., 2003).

Some selective studies have shown poorer performance in depressed

patients as compared with normal controls on tests of attention (e.g., Landro, Stiles,&
Sletvold, 2001; Williams et al., 2000), processing speed (e.g., Basso, Lowery, Neel,
Purdie, & Bomstein), verbal recall (e.g., Fossati, Deweer, Raoux, & Allilaire, 1995;
Ilsley, Moffoot, and O’Carroll, 1995), verbal fluency (e.g., Landro et al., 2001), and
executive functioning (e.g., Ilonen et al., 2000). However, recent meta-analyses have
challenged the conventional notion that neuropsychological deficits accompany major
depression. When stringent methodological designs and only individuals with unipolar
depression (i.e., no evidence of mania or psychoses) were considered, the analyses failed
to provide support for consistent and substantial differences between depressed groups
and normal controls (e.g., Burt, Zembar, & Niederehe, 1995; Veiel, 1997). Ahmad (2004)
used rigorous cluster analytic techniques to further demonstrate that neither depressed
children nor adults were differentiated from controls in terms o f their pattern of
performance

on

a

comprehensive

neuropsychological

test

battery.

Similarly,

neuropsychological performance was not related to symptoms of depression, fatigue, or
medical illnesses in the present sample.
As

previously

mentioned,

self-reported

cognitive

symptoms

and

neuropsychological test performance sometimes do not directly correspond with each
other in clinical practice. Some studies in samples of individuals with HIV infection have
failed to find any association between subjective measures of cognitive difficulties in
everyday situations and neuropsychological test performance (e.g., Minkin et a l, 1996;
Moore et al., 1997; van Gorp et al., 1991), whereas other studies with broader ranges of
cognitive symptoms assessed by the questionnaires and the inclusion of specific domains
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of neuropsychological functioning (in particular processing speed and working memory)
have obtained modest but significant associations (e.g., Bassel et al., 2002; Mapou et al.,
1993; Rourke et al., 1999a). Given the modest effect size, the association between
neuropsychological performance and subjective cognitive complaints observed in larger
samples (e.g., Carter et al., 2003; Rourke et al., 1999a) was not apparent in this smaller
sample of adults with HIV infection.

Clinical Implications and Directions fo r Future Research
Integration of approaches and dissemination of knowledge across research fields
and disciplines is needed to better understand the variable manifestation of specific
clinical symptoms in individuals with HIV/AIDS. This pilot investigation aimed to
accomplish this by integrating biological studies on the neuropathogenesis of HIV within
the broader clinical context by exploring potential biological correlates of commonly
reported symptoms o f cognitive impairments, depression, and chronic fatigue. The major
findings were as follows: (1) neuropsychological impairment was not associated with
serum levels o f biological markers; (2) subjective symptoms, particularly the presence
and severity of depressive symptoms, were related to some measures of immune
activation (i.e., elevated neopterin and mRNA expression of IL-6); and (3) possible non
responders to antidepressant treatment demonstrated elevated immune activation (i.e.,
higher mean serum neopterin levels in “non-responders” as compared with “responders”).
While these preliminary findings require replication in a larger sample, they underscore
the importance of considering multiple etiological factors when interpreting and
managing clinical symptoms on an individual basis. Although the exact mechanisms
underlying these associations cannot be derived from the current analyses, this study
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provides support for the role o f biological processes (either on their own or as mediators
of psychological factors) in the differential expression of clinical symptoms in HIV.
More specifically, elevated serum neopterin levels (measured after the attainment of
therapeutic drug concentrations) may serve to differentiate depressed individuals that are
less likely to respond to antidepressant medications and consequently at greater risk of
developing chronic depression.
The behavioural changes frequently accompanying chronic depression have
significant implications at individual, clinical, and broader social levels. Chronic
depression can adversely impact functioning in everyday life. Higher levels of comorbid
fatigue, cognitive complaints, and general illness symptoms (e.g., headaches, pain,
decreased appetite, and weight loss) in depressed individuals may further exacerbate their
functional limitations. Some depressed individuals may not have the physical and mental
stamina to sustain full-time employment. Financial constraints associated with disability
status may place them in suboptimal living conditions. Deteriorations in physical health
may also result from poor medication adherence or lifestyle changes (e.g., limited
exercise, poor diet, or sleep disturbances). As depressed individuals often withdraw from
social contacts, they are forced to face life’s challenges alone. Mounting psychological
stress without supportive outlets may fuel depressive symptomatology. Alternatively,
substance abuse or engagement in risky sexual behaviours may be used as a means to
superficially cope with the depression and negative views of themselves or others. These
practices can be particularly dangerous given their links to the transmission of HIY.
Furthermore, depressed individuals may maximally utilize health care services in
attempts to manage their psychological and physical discomfort. Clinicians may have
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difficulty detecting comorbid medical conditions as depressive symptoms may
exaggerate certain illness symptoms while masking others. For example, routine
screenings for depression, fatigue, and somatic symptoms need to be directly
incorporated into neuropsychological assessments of individuals with HIV in order to
assess the full significance of self-reported cognitive symptoms in everyday life.
Early identification of antidepressant-resistant patients (i.e., those individuals with
elevated neopterin levels and depressive symptoms after a few weeks of treatment) would
allow clinicians to design and implement alternative interventions (e.g. stress
management techniques/ psychotherapy alone or in combination with drug therapies)
aimed at alleviating their depressive symptoms and ultimately improving their quality of
life. Given the widespread clinical and social implications of chronic depression,
additional research exploring possible biological and psychological explanations for the
differential response to antidepressants in this subgroup is warranted: Do these
individuals

have

greater

rates

of drug metabolism,

quicker

degradation

of

neurotransmitters at synapses, or overstimulation of enzymes that regulate the production
of neurotransmitters? Have these individuals suffered from longstanding depression (i.e.,
prior to their diagnosis o f HIV)? Do they have a normal HPA axis response to stress or is
their hormonal/immune system abnormal due to prolonged chronic stress? Can functional
differences be observed in certain brain regions? Do they operate via specific coping
strategies (e.g., avoidance or negative thinking) that are modifiable by cognitive
behavioural therapy? Can psychosocial factors (e.g., social support) modify this
interaction? Examination of biological factors pre- and post-interventions may also assist
in monitoring the progress of susceptible individuals and may provide a better

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

understanding o f the characteristics that affect differential responses to antidepressant
treatment Prospective research designs that examine the progression of symptoms and
monitor biological changes at regular time intervals may be particularly fruitful in
tracking the pattern of associations. To date, studies on antidepressant effects (including
the present investigation) have been limited by confounding factors. Future research
should attempt to control for the type of antidepressant (i.e., examining the effects of one
antidepressant rather than a mixture of antidepressants) and the duration of treatment. As
well, individual differences rather than group means may provide more insight into the
characteristics of this subsample. During enrolment in the study, it will be important to
define and carefully monitor potential biological changes in response to naturally
occurring stressful transitions points during the course of HIV (e.g., diagnosis of HIV
seropositive status, initiation of HAART, or diagnosis of AIDS) or in response to
unpredictable life stressors (e.g., job loss, breakup of a close relationship, or death of a
family member). Given that variations in the production and cyclic regulation of
hormones exists between the sexes, attention should also be devoted to controlling for sex
differences as well as daily, monthly, and seasonal variations. The collection of multiple
samples over the course of the day or in response to experimental stimulation of the
immune/HP A systems (e.g., lipopolysaccharide challenge, exposure to psychological
stressors, or under dexamethasone suppression) may prove to be more sensitive measures
of biological processes than the isolated serum samples used in the present study. While
the preliminary findings with IL-6 mRNA expression and neopterin levels are intriguing,
verification of these results in a larger follow-study is needed. Future investigations may
wish to expand the psychoneuroimmunological framework to incorporate the role of
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neurotransmitters. Examination of neurotransmitter levels directly and indirectly through
precursor or metabolite concentrations or the activity of enzymes responsible for its
production and degradation would provide supplemental information about the possible
biological mechanisms underlying symptom expression. Furthermore, advancements in
functional imaging techniques may permit the direct evaluation of metabolism or
neurotransmitter function within specific regions (e.g., hypothalamus, hippocampus, and
prefrontal cortex) that contain higher densities of immune/endocrine receptors and have
been proposed to mediate “illness behaviours.”
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APPENDIX A: Preliminary Analyses of HAART-stable participants

Participants
Data was collected for fifteen individuals on a stable HAART regimen for at least
1 Vi years (i.e., HAART-stable). Two individuals were removed from the analyses
because they met one or more of the study exclusionary criteria (see pg. 48).
Demographic data for the HAART-stable group are summarized in Table 14. The sample
was comprised o f all males. Participants were predominantly Caucasian (61%) with the
majority reporting sexual contact (77%) as a major risk factor for HIV infection. Mean
age, education, recent CD4, and recent CD8 were not different between the HAARTnaive and HAART-stable groups. The groups differed in terms of mean lowest CD4 T
cell counts [t (1, 39) = 2.69,p < .01], recent viral load log {t (1,40) = 4.16, p < .001], and
estimated reading level [t (1, 40) = 2.05, p < .05]. The distribution of individuals across
CDC disease stages (CDC: Centers for Disease Control and Prevention, 1992) also
differed between the HAART-naive and HAART-stable groups. Individuals in the
HAART-stable group were at more advanced disease stages: none were asymptomatic
(0%), 4 were mildly symptomatic (30%), and 9 had AIDS-defining illnesses or a nadir
CD4 count of less than 200 (70%).
The means and standard deviations for the biological indicators, symptom
measures, and neuropsychological deficit scores are presented in Table 15. The
distribution

across

levels

of

impairment

on

the

total

and

domain-specific

neuropsychological deficit scores were similar within the HAART-naive and HAARTstable groups, though a greater proportion of individuals within the HAART-stable group
demonstrated moderately to severely impaired performance on the learning efficiency
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domain (compare Tables 7 and 16). This is farther reflected in a greater mean learning
deficit for the HAART-stable as compared with the HAART-naive group [t (1, 42) =
-1.98, p < .05]. No differences were observed between the mean values on any other
measures for the HAART-naive and HAART-stable groups (see Table 15).
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Table 14

'

Demographics for the HAART-stable sample (N =13)

Variables

Mean (Standard Deviation)

Age (years)

39.8 (9.4)

Education (years)

13.5 (2.0)

WRAT reading (SS)

95.4 (8.9)

Recent CD8 Count

1123.2 (515.4)

Recent CD4 Count

412.5 (312.8)

Lowest CD4 Count

224.3 (226.2)

Recent Viral Load Log

2.1 (1.7)
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Table 15
Mean and standard deviations o f the biological indicators, symptom measures, and
neuropsychological deficit scores in the HAART-stable sample (N =13)

Mean (Standard Deviation)

Variables

TNF-alpha mRNA

828.6 (388.3)

IL-6 mRNA

164.3(131.9)

TNF-alpha Elisa "

7.6 (1.1)

IL-6 Elisa

0.6 (0.5)

Neopterin Elisa

7.3 (5.0)

Cortisol Elisa

339.5 (130.5)

BDI Cognitive-Affective5

7.6 (7.5)

Piper Fatigue Total1

3.3 (2.7)

PAOF Total1

38.9 (17.5)

PAOF Memory1

13.6(7.0)

Illness Total1

29.6 (16.8)

Total2

0.98 (0.7)
'y

Processing Speed

0.48 (0.7)

Working Memory/Attention

0.15(0.4)

Learning2

2.31 (1.3)

*Raw scores; 2Composite deficit ratings
Note. BDI = Beck Depression Inventory; PAOF = Patient Assessment
of Own Functioning Questionnaire
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Table 16
Frequencies o f individuals within impairment ranges across total and domain-specific
neuropsychological deficit indices for the HAART-stable sample (n = 13)

Total

Processing
Speed

Working
Memory

Learning
Efficiency

Level of Impairment

n (%)

n (%)

n (%)

n (%)

Average
Mild
Mild to Moderate
Moderate
Moderate to Severe
Severe

3
7
3
0
0
0

9
3
1
0
0
0

11
2
0
0
0
0

3
4
2
3
1
0

(23)
(54)
(23)
(0)
(0)
(0)

(69)
(23)
(8)
(0)
(0)
(0)

(84)
(15)
(0)
(0)
(0)
(0)

(23)
(31)
(15)
(23)
(8)
(0)
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Associations
between
biological
neuropsychological performance

indicators,

symptom

measures,

and

Spearman correlations were separately performed between the biological
indicators, symptom measures, and neuropsychological deficit ratings for the HAARTstable group (see Table 17). However, the analyses are described in terms of interesting
patterns rather than significant findings per se given the small sample size in = 13). For
comparative purposes, individual subjects are plotted for each of the six biological
indicators across total neuropsychological deficit scores (Figures 12 to 17). As shown in
Figures 14 and 15, serum IL-6 (i.e., <11 pg/ml) and TNF-alpha concentrations (i.e., < 20
pg/ml) were well within normal expectations for all individuals. With the exception of
one or possibly two individuals, IL-6 and TNF-alpha mRNA expression were also tightly
clustered (see Figure 12 and 13). This limited variability of these measures in the
HAART-stable group makes it difficult to examine any relative differences across the
symptom and neuropsychological measures. In contrast, there are a few cases above the
clinical reference ranges for both serum neopterin (i.e., > 10 nmol/L) and cortisol (i.e., >
375 nmol/L) (see Figures 16 and 17). Interestingly, all three participants with clinically
elevated neopterin levels showed at least mild to moderate impairment on the total and
learning efficiency deficit ratings. All three individuals with clinically elevated cortisol
levels also demonstrated at least mild to moderate impairment on the total and learning
efficiency domains. No consistent pattern was apparent for these individuals across the
symptom measures.
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Table 17
Spearman correlations ( r j showing the association o f the biological indicators and
measures o f depression, fatigue, cognitive symptoms, and neuropsychological deficit
ratings within the HAART-stable sample (N = 13)

TNF-alpha
mRNA

BDI Cog-Aff1
Piper Fatigue Total1
PAOF Total1
PAOF Memory1
Illness Total1
Total2
Processing Speed2
WM/Attn
Learning2

IL-6
mRNA

TNF-alpha
Elisa

IL-6
Elisa

0.30
-0.03
0.02
0.07
-0.02

-0.36
0.22
-0.18
-0.61*
0.02

0.02
0.16
-0.05
-0.09
0.03

0.37
-0.05
0.38
0.25
0.26

0.21
0.32
0.00
0.20

-0.16
0.08
0.19
-0.28

0.25
0.22
-0.06
0.21

0.25
0.38
0.33
0.15

Neopterin
Elisa

0.35
-0.29
0.03
0.10
-0.02
0.48*
0.22
0.17
0.48*

Cortisol
Elisa

-0.22
-0.13
-0.32
-0.27
0.00
0.35
0.10
0.57*
0.27

1Raw scores; 2Composite deficit ratings
*p < .05 (1-tailed), **p< .01 (1-tailed)
Note. BDI Cog-Aff = Beck Depression Inventory Cognitive-Affective score; PAOF =
Patient Assessment of Own Functioning Questionnaire; WM/Attn = Working Memory
and Attention

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Total deficit rating

Figure 12. Scatterplot showing the relations between TNF-alpha mRNA expression and
total neuropsychological deficit ratings in the FlAART-stable sample.
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Figure 13. Scatterplot showing the relations between IL-6 mRNA expression and total
neuropsychological deficit ratings in the HAART-stable sample.
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Figure 14. Scatterplot showing the relations between serum TNF-alpha concentrations
and total neuropsychological deficit ratings in the HAART-stable sample.
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Figure 15. Scatterplot showing the relations between serum IL-6 concentrations and total
neuropsychological deficit ratings in the HAART-stable sample.
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Figure 16. Scatterplot showing the relations between serum neopterin concentrations and
total neuropsychological deficit ratings in the HAART-stable sample.
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Figure 17. Scatterplot showing the relations between serum cortisol concentrations and
total neuropsychological deficit ratings in the HAART-stable sample.
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